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RESEARCH ARTICLE Cell and Molecular Physiology of the Blood-Brain Barrier
and Choroid Plexus
Choroid plexus glutathione peroxidases are instrumental in protecting the
brain fluid environment from hydroperoxides during postnatal development
Elodie Saudrais,1,2 Nathalie Strazielle,1,2,3 and Jean-François Ghersi-Egea1,2
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Saudrais E, Strazielle N, Ghersi-Egea JF. Choroid plexus gluta-
thione peroxidases are instrumental in protecting the brain fluid
environment from hydroperoxides during postnatal development. Am
J Physiol Cell Physiol 315: C445–C456, 2018. First published June
27, 2018; doi:10.1152/ajpcell.00094.2018.—Hydrogen peroxide, re-
leased at low physiological concentration, is involved in different cell
signaling pathways during brain development. When released at
supraphysiological concentrations in brain fluids following an inflam-
matory, hypoxic, or toxic stress, it can initiate lipid peroxidation,
protein, and nucleic acid damage and contribute to long-term neuro-
logical impairment associated with perinatal diseases. We found high
glutathione peroxidase and glutathione reductase enzymatic activities
in both lateral and fourth ventricle choroid plexus tissue isolated from
developing rats, in comparison to the cerebral cortex and liver.
Consistent with these, a high protein expression of glutathione per-
oxidases 1 and 4 was observed in choroid plexus epithelial cells,
which form the blood-cerebrospinal fluid barrier. Live choroid plex-
uses isolated from newborn rats were highly efficient in detoxifying
H2O2 from mock cerebrospinal fluid, illustrating the capacity of the
choroid plexuses to control H2O2 concentration in the ventricular
system of the brain. We used a differentiated cellular model of the
blood-cerebrospinal fluid barrier coupled to kinetic and inhibition
analyses to show that glutathione peroxidases are more potent than
catalase to detoxify extracellular H2O2 at concentrations up to 250
M. The choroidal cells also formed an enzymatic barrier preventing
blood-borne hydroperoxides to reach the cerebrospinal fluid. These
data point out the choroid plexuses as key structures in the control of
hydroperoxide levels in the cerebral fluid environment during devel-
opment, at a time when the protective glial cell network is still
immature. Glutathione peroxidases are the main effectors of this
choroidal hydroperoxide inactivation.
blood-CSF barrier; cerebrospinal fluid; hydrogen peroxide; neuropro-
tection; perinatal
INTRODUCTION
In physiological conditions, the brain produces reactive
oxygen species (ROS) due to its particularly large cerebral
oxygen consumption. Mitochondrial oxidative metabolism and
NADPH-oxidase enzymatic activities generate superoxide an-
ion radicals O2. which are quickly disproportionated to hy-
drogen peroxide (H2O2), either spontaneously or enzymatically
by superoxide dismutases (54, 63). During brain development,
certain ROS act as signaling molecules in neurogenesis, neu-
ronal polarization, and maturation. In particular, H2O2, re-
leased at low physiological concentration, is involved in dif-
ferent cell signaling pathways in an autocrine and paracrine
manner (7, 20, 63). Hence, its extracellular level needs to be
tightly controlled.
When produced in excess, H2O2 may initiate lipid peroxi-
dation, protein, and nucleic acid damage. The iron-mediated
formation of the highly reactive hydroxyl radical ·OH, result-
ing from H2O2 decomposition through the Fenton reaction, is
especially damaging (9). The hydroxyl radical ·OH reacts with
polyunsaturated fatty acids which are enriched in brain during
development (10, 44), thereby initiating lipid peroxidation. The
propagation of lipid peroxidation through membranes alters
their fluidity and permeability and generates toxic lipid hy-
droperoxide and aldehyde by-products. The latter can easily
diffuse through membranes and modify nuclear proteins (3).
The perinatal period is a high-risk period for neurological
impairment through exposure to inflammation, preeclampsia,
perinatal hypoxia, or deleterious exogenous environmental
toxicants and drugs (1, 4, 26, 35, 61). All of these factors are
prone to increase oxidative stress including H2O2 release and
subsequent lipid peroxidation in the brain during this critical
period of maturation.
Many antioxidant systems control ROS levels. These in-
clude enzymes such as superoxide dismutases, catalase, per-
oxiredoxins, glutathione peroxidases (GPxs) and its companion
enzyme glutathione reductase (GR), as well as reducing mol-
ecules such as glutathione (GSH), bilirubin, and vitamins C
and E (49). In adult brain, glial cells, in particular astrocytes
and oligodendrocytes, are the main cells contributing to the
brain antioxidant defense capacity (5, 15, 21, 43). As an
example, catalase activity in astrocytes could protect neurons
from extracellular H2O2 (14). The control of ROS levels may
not be as efficient during peri/postnatal brain development. The
astrocytic network is not fully formed, as astrocyte differenti-
ation and maturation is largely postnatal (13, 64). Oligoden-
drocytes are also immature and have low GPx activities as
compared with the mature cells (5).
A pioneer work in the field of blood-brain interfaces de-
scribed high levels of antioxidant enzymatic activities, espe-
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cially GPx activity, in the lateral ventricle choroid plexuses
(CPs) of adult rats (60). Glutathione-dependent peroxidase
activity is mediated by multiple GPx isoenzymes that all accept
H2O2 as a substrate, while some of them also inactivate lipid
hydroperoxides including signaling molecules (8). The CPs
located in the lateral, 3rd, and 4th ventricles of the brain in all
mammals form the barrier between the blood and the ventric-
ular cerebrospinal fluid (CSF) that they secrete. They are the
most vascularized brain structures and display the highest
blood flow, especially during peri/postnatal development. They
grow and differentiate early in the course of fetal development
(18). They constitute an important site of blood-brain ex-
changes during this period (24) and already display various
mature neuroprotective functions toward blood-borne toxicants
at birth in rat (40).
Hydrogen peroxide is a reactive, yet relatively long-lasting,
molecule. It circulates through extracellular fluid and CSF
where its level increases in severe postnatal pathological con-
ditions (32, 33, 36, 41). When released at supraphysiological
concentration, H2O2 can induce oxidative damage such as lipid
peroxidation at a distance from the source. Such noxious action
can be exacerbated through the Fenton reaction, a mechanism
that occurs in CSF (55). This prompted us to test the hypothesis
that the CPs actively inactivate hydroperoxides in their envi-
ronment during development and that choroidal GPxs are the
main effectors of this inactivation.
MATERIALS AND METHODS
Primary antibodies. Anti-GPx1 rabbit polyclonal antibody (Ab)
(ab22604, Abcam, Cambridge, UK), anti-GPx4 rabbit polyclonal Ab
(14432-1-AP, Proteintech, Manchester, UK), anti-GR rabbit poly-
clonal Ab (GTX114199, GeneTex, Irvine, CA), anti-RECA-1 mouse
monoclonal Ab (clone HIS52, MCA970, Bio-Rad, Hercules, CA),
anti-Na-K-ATPase mouse monoclonal Ab (NB300-146, Novus
Biologicals, Littleton, CO), and anti-actin mouse monoclonal Ab
(A1978, Sigma-Aldrich, St. Louis, MO) were used.
Tissue collection. Animal care and procedures were approved and
conducted according to the guidelines approved by the French ethical
committee (decree 87-848) and by the European community directive
(86-609-EEC). Specific pathogen-free Sprague-Dawley rats (RjHan:
SD), either 5-wk-old (W5) or 12-wk-old (W12) males (200 and 500 g,
respectively) and females (180 and 300 g, respectively), as well as
females with litters, were obtained from Janvier (Le Genest-Saint-Isle,
France). All animals were kept in a conventional facility, in standard
cages enriched with paper, with free access to pellet food and tap
water, under a controlled environment (12-h daylight cycle, 22°C).
Animals were euthanized by decapitation under isoflurane anesthesia,
and brain and liver were rapidly excised and placed at 4°C in
Krebs-Ringer buffer (135 mM NaCl, 4 mM KCl, 2.2 mM CaCl2, 1.2
mM MgCl2, 6 mM NaHCO3, 10 mM HEPES, 5 mM glucose, pH 7.4).
The two lateral ventricle CPs and the 4th ventricle CP were micro-
dissected under a stereomicroscope and kept separately. Brain cortices
were sampled and cleaned of apparent meninges. Choroid plexuses
were either used extemporaneously for metabolism studies or were
pooled (between 2 and 12 CPs, depending on developmental stage),
rapidly frozen, and kept at 80°C for further enzymatic measurement
or Western blot analysis. For immunohistochemistry, brains sampled
from 2-day-old (P2) and 9-day-old (P9) animals were snap-frozen in
isopentane at 40°C and kept at 80°C.
Cell isolation and primary cultures. Primary cultures of CP epi-
thelial cells were prepared as previously described (56, 57). The CP
epithelial cells were cultured on laminin-coated microporous Trans-
well polycarbonate filter inserts (0.33 cm2 surface, 0.4 m pore size;
Corning Life Sciences, Amsterdam, Netherlands) in culture medium
consisting of Ham’s F-12 and Dulbecco’s modified Eagle’s medium
(1:1) supplemented with 10% fetal calf serum, 2 mM glutamine, 50
g/ml gentamicin, and several growth factors as previously reported
(57). The culture medium was renewed every other day, and the cell
monolayer was used for metabolic and permeability studies 7 to 8
days after culture was initiated.
Enzymatic activity measurements. Choroidal tissue, cerebral corti-
ces, and liver were sampled from P2, 7-day-old (P7, for GPx), P9 (for
GR), 17-day-old (P17), and W5 (male and female) rats. Tissues were
homogenized at 4°C in a 50 mM Tris·HCl, 0.1 mM EDTA buffer, pH
7.4, using a Tenbroeck homogenizer. Glutathione peroxidase and GR
enzymatic activities were measured by kinetic spectrophotometry as
previously described (60). Briefly, GPx activity was measured at 37°C
in a Carry 100 spectrophotometer (Varian, Pao Alto, CA) in 500 l
homogenization buffer, containing 1 IU GR (10105678001, Sigma-
Aldrich), 0.5 mM GSH (G6529, Sigma-Aldrich), 0.12 mM nicotin-
amide adenine dinucleotide phosphate (NADPH, N6505, Sigma-
Aldrich), and 0.2 mM H2O2 (95321, Sigma-Aldrich) as substrate. The
complete assay mixture without the protein homogenate was used to
assess the low nonenzymatic degradation of NADPH due to H2O2.
The kinetic parameters, Michaelis constant Km, and maximum veloc-
ity Vmax were determined in homogenates prepared from either a mix
of lateral ventricle and 4th ventricle CPs from P9 animals or from
cultured CP epithelial cells, by varying H2O2 concentration between
1 and 200 M.
Activity measurements for GR were conducted in 500 l homog-
enization buffer, containing 0.2 mM oxidized glutathione (GSSG,
G4376, Sigma-Aldrich) and 0.12 mM NADPH as substrate. For both
assays, the rate of NADPH oxidation was recorded over a 10-min
period at 340 nm. The total protein content of the samples was
determined by the method of Peterson with bovine serum albumin as
the standard (47).
Western blot analysis. Samples were homogenized using a Ten-
broeck homogenizer in homogenization buffer (250 mM sucrose, 50
mM K2HPO4/KH2PO4, 1 mM EDTA, 0.1 mM dithiothreitol, pH 7.4)
supplemented with protease inhibitors (Complete, Roche, Penzberg,
Germany). Samples were denatured in Laemmli buffer (final concen-
tration: 62.5 mM Tris base, 1% sodium dodecyl sulfate, 10% glycerol,
0.01% bromophenol blue (all wt/vol), 0.1 mM dithiothreitol, pH 6.8)
and heated for 10 min at 95°C. Proteins were separated on a 10%
Criterion XT Bis-Tris gel (Bio-Rad) run in MOPS buffer (no.
1610788, Bio-Rad) at 70 V for 10 min, followed by 120 V for 2 h. The
gel was blotted to 0.2 m nitrocellulose membrane (no. 10600001,
GE Healthcare Life Sciences, Coventry, UK) in transfer buffer (25
mM Tris, 192 mM glycine, 20% methanol) for 40 min. After assess-
ment of the transfer quality by Ponceau red staining, the membrane
was incubated in 5% skimmed milk in Tris-buffered saline (TBS; 50
mM Tris base, 150 mM NaCl, pH 7.4) containing 0.1% Tween 20
(TBST) at room temperature (RT) for 1 h. Primary Abs were diluted
in 2% skimmed milk in TBST, at 1 g/ml for anti-GPx1 and 2 g/ml
for anti-GR. The mouse anti-actin monoclonal Ab was used at a final
dilution of 0.05 g/ml. Membranes were incubated at 4°C overnight,
then washed three times for 10 min in TBST at RT. Horseradish
peroxidase-conjugated secondary Abs from Jackson ImmunoResearch
(Baltimore, MD) were donkey anti-rabbit IgG (711-036-152) used at
a final concentration of 0.05 g/ml for GPx1 detection and 0.08 g/ml
for GR detection, and donkey anti-mouse IgG (715-036-151) used at
a final concentration of 0.05 g/ml for actin detection. After two
washings in TBST and two others in TBS, membranes were exposed
to a chemiluminescent horseradish peroxidase substrate (SuperSignal
West Pico Chemiluminescent Substrate, Thermo Scientific, Waltham,
MA) for 5 min, and exposed to X-ray films (Amersham Hyperfilm
ECL, 28906837, GE Healthcare, or CL-Xposure Film, 34089, Thermo
Scientific).
As an index of Ab quality, only one band specific for GPx1 (26.3
kDa) was observed in CP and liver homogenates from postnatal rat,
besides an additional signal (200 kDa) present in all samples. One
C446 CHOROIDAL GPxs IN THE DEVELOPING BRAIN
AJP-Cell Physiol • doi:10.1152/ajpcell.00094.2018 • www.ajpcell.org
Downloaded from www.physiology.org/journal/ajpcell by ${individualUser.givenNames} ${individualUser.surname} (193.054.110.033) on December 16, 2018.
band specific for GR (52.2 kDa) was observed in CPs and cerebral
cortex (weak signal), and two bands were observed in liver homog-
enate (52.2 and 55 kDa), besides an additional signal (30 kDa) present
in all samples.
Immunohistochemical analysis. Section (12 m thick) were pre-
pared from rat brains using a Cryostar NX50 cryostat (Thermo
Scientific), mounted on glass slides, air-dried at RT, and kept at
20°C. Sections were fixed in 4% paraformaldehyde at RT for 10
min. For GPx1 immunohistochemical analysis, epitope retrieval was
performed using a microwave treatment (3  5 min at 850 W) in 0.01
M citrate buffer, pH 6. After 1 h of saturation at RT in a blocking
solution containing 1% bovine serum albumin, and 10% normal goat
serum (S-1000, Vector, Burlingame, CA) in phosphate-buffered saline
(PBS, pH 7.4) containing 0.3% Triton X-100 (PBS-T), sections were
incubated at 4°C overnight with anti-GPx1, anti-GPx4, anti-RECA-1,
or anti-Na-K-ATPase primary Abs diluted in blocking solution.
Final concentrations were 2, 4.1, and 2.5 g/ml for anti-GPx1,
anti-GPx4, anti-RECA-1 Abs, respectively. Anti-Na-K-ATPase
primary Ab was diluted 2,000 times. Negative controls were per-
formed by omitting the primary Ab. After five washes for 7 min at RT
in PBST, sections were incubated for 1 h at RT with secondary
goat-anti-rabbit Ab (Alexa Fluor 488, A11006, Invitrogen, Carlsbad,
CA) or secondary goat-anti-mouse Ab (Alexa Fluor 555, A21422,
Invitrogen) at a final concentration of 0.2 g/ml. After three washes
for 5 min in PBS-T, and two washes for 5 min in PBS at RT,
diamidine-2-phenylindole-dihydrochloride (DAPI, 236276, Roche
Diagnostics, Basel, Switzerland) was used as fluorescent nuclear stain
at 0.1 g/ml in PBS. Sections were washed again five times in PBS.
After the slides were mounted with Fluoprep (BioMerieux, Marcy
l’Etoile, France), immunofluorescence was viewed and analyzed us-
ing an Imager Z1 fluorescence microscope equipped with a Digital
Camera (Zeiss, Jena, Germany). Images were acquired using Ax-
ioVs40 software (version 4.8, Zeiss).
Hydrogen peroxide concentration measurement. Hydrogen perox-
ide was quantified in a microtiter plate as previously described (17).
Five to 100 l samples of incubation buffer were collected and
immediately added to 150 l of reaction mixture containing 0.5 mM
(NH4)2Fe(SO4)2, 0.2 mM xylenol orange, and 200 mM sorbitol in 50
mM H2SO4. All volumes were adjusted to 250 l using Ringer
HEPES buffer (RH, 150 mM NaCl, 5.2 mM KCl, 2.2 mM CaCl2, 0.2
mM MgCl2, 6 mM NaHCO3, 2.8 mM glucose, 5 mM HEPES, pH
7.4). After 45 min of incubation at RT under gentle agitation, the
absorption at 540 nm was measured using a plate reader Infinite 200
(Tecan, Männedorf, Switzerland). Standard H2O2 solutions prepared
extemporaneously in RH were used for calibration.
Hydrogen peroxide inactivation by isolated live choroid plexuses.
Choroid plexuses freshly dissected from either the 4th or lateral
cerebral ventricles of P2 rats were warmed up in RH at 37°C for 10
min. They were transferred to 150 l of 50 M H2O2 in RH. The
incubation medium was sampled every 10 min for 30 min and assayed
for H2O2. In the absence of CPs, H2O2 concentration did not change
in the medium during the time of the experiment. At the end of the
experiment, CPs were collected, digested in 1 M sodium hydroxide,
and their protein content was measured.
The remaining H2O2 quantity data were plotted against time and
fitted to an exponential equation using CurveExpert 1.4 software. The
half-life of H2O2 in this ex vivo experimental setting (t1/2 ex vivo) was
determined for each type of CP, and the initial clearance of elimina-
tion Clel was calculated as follows:
Clel  Vd ex vivo 
Ln2
t1⁄ 2 ex vivo
(1)
where the volume of distribution Vd ex vivo is the incubation volume.
For each type of CP, the in vivo half-life of H2O2 (t1/2 in vivo) was
extrapolated from the initial clearance of elimination Clel as follows:
t1/2 in vivo  Vd in vivo 
Ln2
Clel
(2)
where the volume of distribution Vd in vivo is the volume of either the 4th
ventricle or both lateral ventricles of P2 rats as previously reported (22).
In vitro blood-cerebrospinal fluid barrier permeability and meta-
bolic studies. Cells were rinsed twice with RH at 37°C and were either
basolaterally exposed to H2O2 concentrations varying between 20 and
500 M in 400 l of RH or apically exposed to 60 and 100 M H2O2
in 150 l of RH. During 15 min (for 20 M H2O2) or 40 min (for all
other concentrations), the medium was sampled regularly (5 to 100
l) from both chambers and assayed for H2O2. Hydrogen peroxide
was stable in these experimental conditions in the absence of cells.
The total protein content of each cell monolayer was determined.
For each concentration used, the remaining H2O2 quantity data
were plotted against time and the initial part of those plots was fitted
according to the following equation:
Qt H2O2  Q0 H2O2  e
kelt (3)
where Qt H2O2 is the total amount of H2O2 remaining in both the apical
and basolateral compartments at time t, Q0 H2O2 is the initial quantity
of H2O2 in the basolateral compartment, and kel is the initial elimi-
nation rate constant.
These kel values were used to calculate the H2O2 elimination
half-life t1/2 and the initial H2O2 elimination rate  for each concen-
tration, according to:
t1⁄2 
Ln2
kel
(4)
and
 
Q0 H2O2  kel
Qprot
(5)
where Qprot is the protein content.
In the range of H2O2 concentrations used, the catalase activity can
be assimilated to a first-order reaction as the Michaelis constant of this
enzyme Km catalase is unusually high, above 1 M (37). The respective
involvement of catalase and GPxs in H2O2 metabolism was thus
modeled by a nonlinear regression analysis of  over H2O2 concen-
tration (CurveExpert 1.4) using the following equations:
  vcatalase  vGPx (6)
where
catalase
Vmax catalase  Q0 H2O2
Km catalase
(7)
and
GPx 
Vmax GPx  Q0 H2O2
Km GPx  Q0 H2O2
(8)
from where the Michaelis constant Km and the maximum velocity
Vmax for the GPx-dependent activity can be obtained.
In some experiments, cells were preincubated with enzyme inhib-
itors, 50 M 1-chloro-2,4-dinitrobenzene (CDNB) added in the ba-
solateral compartment for 20 min, 10 mM 3-aminotriazole (3-AT)
added in both compartments for 150 min (16), or a combination of
3-AT and CDNB added sequentially. CDNB acts by fully depleting
cells from GSH (25), thus abolishing GPx activity. After preincuba-
tion, cells were basolaterally exposed to 50 M H2O2 in the presence
of the inhibitors. Incubation media were sampled after 20 min and
assayed for H2O2. Data are expressed as permeability coefficient Pt as
described in detail elsewhere (38). Sucrose permeability was mea-
sured during the course of the inhibitor study in a separate experiment.
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Briefly, inserts preincubated with inhibitors were placed in wells of a
12-well plate containing 400 l of RH with [14C]sucrose (MC 266,
Hartmann Analytic, Glattbrugg, Switzerland), 50 M H2O2 and
inhibitors, and the apical medium was replaced by 150 l of fresh
buffer containing the inhibitor in the case of 3-AT-treated cells. At
regular intervals after addition of the insert, an aliquot of 100 l was
removed from the apical chamber and replaced with an equal volume
of fresh identical buffer. Radioactivity was determined by liquid
scintillation counting using a -counter (Canberra Tricarb 1600TR,
Packard, Groningen, Netherlands). Clearance curves were generated
as previously described in detail (38, 58).
Statistical analysis. Results are expressed as means  SD for
enzymatic activity data and in vitro inhibition studies, and as means 
SE for all other data. Data were subjected to one-way (in vitro
inhibition studies) or two-way ANOVA analysis with Dunnett’s post
hoc test for comparisons to a single control or with a Tukey-Kramer’s
post hoc test for multiple comparisons between groups. A P value 	0.05
was considered statistically significant. All analyses were performed with
Prism software (version 7.04, Graph Pad, San Diego, CA).
RESULTS
Choroid plexuses display high enzymatic activities and pro-
tein levels for glutathione peroxidases and glutathione reduc-
tase during postnatal development. The GPx and GR-specific
activities were measured at different developmental stages in
brain tissue as well as in the liver, the reference organ for
metabolism (Fig. 1). It has in particular a high potential for
ROS production (45), and displays high levels of selenium-
dependent GPx activity (27, 66). Glutathione peroxidase-spe-
cific activity in CPs was already high at P2 and P7, being twice
the activity measured in the liver at similar ages (Fig. 1A).
Choroidal GPx activity was also higher by one order of
magnitude in comparison to the activities measured in the
cerebral tissue at all developmental stages investigated (Fig.
1A). These GPx activities increased 1.8-fold and 2.2-fold from
P2 to W5 (males and females combined) in lateral ventricle
CPs and 4th ventricle CP, respectively, and remained steady or
decreased from W5 to W12. The CP-to-cerebral cortex activity
ratio was, however, maximal at P17 and decreased thereafter
(Table 1). Male and female animals were analyzed separately
after weaning. In liver, GPx-specific activity was 2.1 and 2.5
times higher in females than in males at W5 and W12,
respectively, while no sex difference was observed in brain
tissues (Fig. 1A). Glutathione reductase, which allows to re-
generate reduced GSH following hydroperoxide reduction by
GPxs, was also consistently more active in both CPs than in the
cerebral cortex at all developmental stages investigated (Fig.
1B). Yet, CP-to-cerebral cortex activity ratios were lower than
Fig. 1. Glutathione peroxidase and glutathi-
one reductase activities in choroid plexuses,
cerebral cortex, and liver during postnatal
development in rat. A: glutathione peroxi-
dase-specific activity. Activities are ex-
pressed as nmol reduced H2O2·min1·mg
protein1. Results are means  SD (n  3).
**,***Statistically different from the previ-
ous developmental stage, P  0.01 and P 
0.001, respectively. $$$Statistically different
from male tissue at corresponding develop-
mental stage, P 	 0.001. Other significant
statistical differences not appearing on the
graph are as follows: glutathione peroxidase
activities in both types of choroid plexuses
(CPs) are different from those measured in
cerebral cortex at corresponding develop-
mental stages (P  0.001). All analyses:
two-way ANOVA with Tukey-Kramer’s
multiple comparisons test. B: glutathione re-
ductase-specific activity. Activities are ex-
pressed as nmol NADP·min1·mg pro-
tein1. Results are means  SD (n  4).
**,***Statistically different from the previ-
ous developmental stage, P  0.01 and P 
0.001, respectively. Other statistical differ-
ences not appearing on the graph are as
follows: glutathione reductase activities in
both types of CPs are different from those
measured in cerebral cortex at corresponding
developmental stages (P  0.001). All analy-
ses: two-way ANOVA with Tukey-Kramer’s
multiple comparisons test. GPx, glutathione
peroxidase; GR, glutathione reductase; LVCP,
lateral ventricle choroid plexus; P2, 2-day-old;
P7, 7-day-old; P9, 9-day-old; P17, 17-day-old;
W5, 5-wk-old; W12, 12-wk-old; 4VCP, 4th
ventricle choroid plexus.
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those calculated for GPx activities. The hepatic GR-specific
activity was significantly higher in W5 and W12 than in
younger animals. Conversely, choroidal GR activities were
already high at birth.
The high GPx and GR-specific activities measured in CPs in
comparison to cortical tissue were correlated to higher GPx1
and GR protein levels measured by Western blotting at P2
(data not shown) and P9 (Fig. 2A). Also in agreement with
Table 1. Glutathione peroxidase-specific activity in choroid plexuses vs. cerebral cortex at early stages of postnatal
development and in adult
GPx Activity Ratio P2 P7 P17
Male Female
W5 W12 W5 W12
4VCP/Cx 15.5  0.9* 21.8  2.1* 37.4  2.1 13.1  1.2* 15.3  2.5* 29.4  5.2* 8.9  0.5*
LVCP/Cx 18.8  4.7* 28.8  2.2* 41.1  2.7 12.3  3.0* 22.5  3.8* 28.3  4.1* 13.1  1.8*
Values are means  SD (n  3). Statistical differences are shown relative to P17. GPx, glutathione peroxidase; P2, 2-day-old; P7, 7-day-old; P17, 17-day-old;
W5, 5-wk-old; W12, 12-wk-old; 4VCP: 4th ventricle choroid plexus; LVCP, lateral ventricle choroid plexus; Cx, cerebral cortex. *P  0.001, one-way ANOVA
with Dunnett’s multiple comparisons test.
Fig. 2. Expression and localization of glutathione peroxidase 1 (GPx1), glutathione peroxidase 4 (GPx4), and glutathione reductase (GR) in postnatal rat choroid
plexuses. A: Western blot analysis of GPx1 and GR expression in 9-day-old rat choroid plexuses (CPs) from the 4th (4V) and the lateral ventricles (LV), cerebral
cortex (cx) and liver (li) (top). Representative signals obtained from whole tissue homogenates are shown (15 g of protein per lane for GPx1, 35 g for GR).
For each Western blot, actin used as a loading indicator is shown in bottom panels. Protein expression of both enzymes is higher in CPs than in cerebral cortex.
GPx1 expression is also higher in CPs than in liver. Actin level in liver is lower than in other organs (53), explaining the difference in signal intensity between
liver and CPs for equal amounts of protein loaded. B: immunohistochemical detection of GPx1 and GPx4 in CPs of 2-day-old rats. a–e: labeling of GPx1 (green)
and Na-K-ATPase (red, b, c, d) in both 4th ventricle (a, b) and lateral ventricle (c, d, e) CPs. Staining of Na-K-ATPase allows to delineate the apical
membrane of CP epithelial cells and to associate GPx1 activity with the intracellular compartment of these cells. The GPx1 signal is not detected in CP
conjunctive stroma (stars). It was also undetected or was low in the brain parenchyma and in the ependyma, in comparison to CP epithelial cells (d). f–h:
colabeling of GPx4 (green) and Na-K-ATPase (f, red) or RECA-1 (red, a marker of choroidal vessels, arrowhead in g) shows that the GPx4 signal is restricted
to the intracellular compartment of CP epithelial cells in both 4th (f) and lateral (g) ventricle CPs. The GPx4 signal is low or undetectable in brain parenchyma
(data not shown) and in CP conjunctive stroma (f, g, stars). DAPI was used for nucleus staining (blue). Inset in a, e, h: negative controls obtained by omitting
the primary Abs. Scale bars, 20 m. CSF, cerebrospinal fluid; ep, ependyma; LVCP, lateral ventricle choroid plexus; 4VCP, 4th ventricle choroid plexus.
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enzymatic activity data, GPx1 protein expression was higher at
P9 in CPs than in liver, and GR protein expression was similar
between the two types of tissue (Fig. 2A). The early postnatal
expression of both GPx1 and GPx4 in the CPs was also
observed by immunohistochemistry (Fig. 2B). All choroidal
loops were labeled. Colabeling with Na-K-ATPase used as
a marker of the apical membrane of the choroidal epithelium,
and RECA-1 used as a marker of choroidal blood vessels,
showed that the localization of both GPx1 and GPx4 in CPs is
restricted to the epithelial cells forming the blood-CSF barrier,
where they distribute throughout the cytoplasm (Fig. 2B).
Choroid plexuses efficiently and rapidly inactivate hydrogen
peroxide from the cerebrospinal fluid environment. To evaluate
whether the high GPx activities measured in CP homogenates
confer to this tissue the capacity to efficiently inactivate H2O2
present in CSF, live and intact CPs were isolated from P2
animals, kept in RH used as mock CSF, and exposed to 50 M
H2O2. In the absence of CPs, H2O2 concentration did not
change in the medium during the time of the experiment (Fig.
3). The 4th ventricle CP and the lateral ventricle CPs were
analyzed separately. In this experimental setup, CPs are ex-
posed to H2O2 at their apical CSF-facing membrane. The
amount of H2O2 remaining in the mock CSF was plotted
against time (Fig. 3). Although the CPs were incubated in a
large volume of mock CSF as compared with the actual
ventricular volumes of P2 rat pups (Table 2, Vd in vivo), both
types of CPs had the ability to rapidly catabolize H2O2.
Differences between the amount-over-time curves generated
for the two types of CPs can be explained by the difference in
tissue size: two CPs of the lateral ventricle and one CP of the
4th ventricle contain 100 and 69 g protein, respectively (22).
The ex vivo H2O2 half-life t1/2 ex vivo calculated from the
amount-over-time curves presented in Fig. 3 are reported in
Table 2, together with the initial clearance of elimination (Clel).
Assuming the latter value to be identical for isolated live CPs
(ex vivo condition) and for in situ CPs (in vivo condition), we
calculated the in vivo half-life t1/2 in vivo of 50 M H2O2 in
CSF, based on actual ventricular volumes Vd in vivo measured in
P2 animals (Table 2). The t1/2 in vivo values are in the order of
a few seconds for lateral ventricle CPs and half a minute for the
4th ventricle CP, demonstrating the high efficiency of these
tissues to inactivate CSF-borne H2O2.
Glutathione peroxidases are the main H2O2 detoxifying
enzymes in choroid plexuses. Hydrogen peroxide is detoxified
by two enzymatic systems, GPxs and catalase. To investigate
the mechanism of H2O2 inactivation in the CP epithelium and
establish the relative participation of GPxs in that process, we
used an in vitro cellular model of the blood-CSF barrier (Fig.
4A). The monolayers of CP epithelial cells grown on a perme-
able membrane recapitulate the tightness and polarity of the
choroidal epithelium in vivo. They have been validated for
barrier and transport functions and used to study metabolic func-
tions involving GSH (25, 40, 56, 57). This model offers several
advantages over isolated CP experiments, allowing 1) to expose
either the CSF or the blood side of the barrier to H2O2, 2) to apply
long-term exposures to inhibitors, 3) to measure the blood-CSF
barrier permeability to H2O2, and 4) to limit the number of
animals to be used for mechanistic studies.
We first established whether the CP epithelial cells of this
model maintain the high GPx-specific activity observed in CPs
of postnatal rats. Cultured CP epithelial cells presented a
GPx-specific activity of 200.8  57.0 nmol·min1.mg pro-
tein1 (mean  SD, n 
 5 measurements from 2 batches of
cells); this activity is similar to that of CP postnatal rats (Fig.
1). When cells were exposed to 60 M H2O2 at either their
basolateral or their apical membrane, H2O2 disappeared
equally rapidly from the medium. The amounts of H2O2
reduced over a 14-min period were 213.0  63.69 and 164.4 
20.8 nmol/mg protein for the basolateral and apical application,
respectively (means  SD, n 
 4, not statistically different,
two-tailed t-test for unequal variance). Similar observations
were made when using higher H2O2 concentration (100 M,
data not shown). To assess whether the detoxification could
result in part from enzymatic or nonenzymatic antioxidant
components secreted by the cells, other cell monolayers were
rinsed and incubated in fresh RH. The conditioned media were
then sampled after 7.5 and 25 min of cell contact and imme-
diately incubated with 44 M H2O2 for identical periods.
Inactivation of H2O2 was not observed (Table 3), indicating
that H2O2 needs to diffuse into the cells to be detoxified.
Table 2. Ex vivo experimental and in vivo modeled choroid
plexus-dependent H2O2 elimination parameters
Ex Vivo (Assay) In Vivo (Modeling)
Vd ex vivo, l t1/2 ex vivo, min
Clel, l·min1·mg
protein1 Vd in vivo, l* t1/2 in vivo, min
4VCP 150 17.2  2.4 113.0  13.3 6.56 37.6  5.5
LVCP 150 9.6  0.3 123.7  6.1 2.95 10.0  0.5
Values are means  SE (n  4). Data were generated with a 50 M H2O2
initial concentration. LVCP, lateral ventricle choroid plexus; 4VCP, 4th
ventricle choroid plexus. See MATERIALS AND METHODS for definition of H2O2
elimination parameters and details on calculations. *Vd in vivo is ventricular
volume measured in 2-day-old rat pups (22).
Fig. 3. Isolated choroid plexuses (CPs) detoxify extracellular H2O2. Two CPs of
the lateral ventricles or one CP of the 4th ventricle was exposed to Ringer HEPES
buffer containing 50 M H2O2. For each batch of CPs, protein content was
measured to normalize the initial H2O2 quantity for the average protein content of
CPs isolated from 2-day-old Sprague-Dawley animals. These protein contents are
100  9 g for lateral ventricle CP and 69  9 g for 4th ventricle CP (22). Data
show amount of H2O2 remaining in the incubation medium over time, expressed
as a percentage of the initial H2O2 amount in the incubation medium
(means  SE; n 
 5). Ctrl, control incubation without CPs; LVCP, lateral
ventricle choroid plexus; 4VCP, 4th ventricle choroid plexus.
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To allow the use of low concentrations of H2O2 yet com-
patible with the detection limit of the assay, and to explore the
existence of a metabolic blood-to-CSF barrier to H2O2, all
subsequent experiments were performed by adding H2O2 into
the larger basolateral compartment. The kinetic parameters of
H2O2 elimination in the choroidal epithelium were determined
by exposing the cells to H2O2 concentrations ranging from 20
to 450 M. The amount of H2O2 remaining in the whole
system (apical  basolateral media) was plotted against time
(Fig. 4B). The data show that CP epithelial cells efficiently
inactivated H2O2, whichever initial concentration in the baso-
lateral compartment is applied. The linear part of the log
representation of these elimination curves (Fig. 4B, inset)
provides for each concentration the period that can be used to
determine the initial elimination rate constants kel (Table 4).
Those values were used to calculate H2O2 elimination half-life
t1/2 for each concentration (Table 4). The decrease in t1/2 values
as a function of decreasing H2O2 concentrations indicates that
the elimination process involves a saturable component. To
further investigate the mechanism, we calculated the initial
H2O2 elimination rates  from kel values and plotted them
against the initial H2O2 concentration (Fig. 4C, solid line).
Curve fitting analysis was performed on the assumption that
H2O2 elimination results from two coexisting enzymatic reac-
tions (see MATERIALS AND METHODS, Eq. 6). The curves corre-
sponding to the mixed-order reaction attributed to GPxs (Eq. 8)
and the first-order reaction attributed to catalase (Eq. 7) are
shown in Fig. 4C (dashed and dotted line, respectively). The
respective  values for GPx and catalase activities, calculated
for each concentration (Table 4), indicate that GPx activity is
dominant in H2O2 inactivation when the initial concentration is
Fig. 4. Kinetics of H2O2 detoxification by rat
choroid plexus epithelial cells. A: schematic
representation of the in vitro blood-cerebro-
spinal fluid (CSF) barrier. Choroid plexus
(CP) epithelial cells are cultured on a porous
filter and reproduce a choroidal cell layer
separating a CSF-mimicking apical compart-
ment from a blood- and stroma-mimicking
basolateral compartment. B: amount of H2O2
remaining in the incubation medium over
time as a function of the initial H2O2 con-
centration. Choroid plexus epithelial cells
were exposed to 20 (o), 50 (Œ), 200 (□), or
450 () M H2O2 during 15 min (for H2O2
20 M) or 40 min (for all other concentra-
tions). H2O2 quantity expressed in nmol/mg
protein represents means  SE (n 
 4 cell-
covered filter inserts). The average amount
of total protein contained in epithelial cell
monolayers was 0.129 mg protein/cm2). In-
set: semilogarithmic representation of data
obtained during the initial period of expo-
sure to H2O2. C: H2O2 initial elimination
rate  (solid line), and modeled H2O2 elim-
ination rates dependent on catalase (dotted
line) and glutathione peroxidases (dashed
line) (cf. MATERIALS AND METHODS). D:
Hanes-Woolf plot of glutathione peroxidase
kinetic parameters in cultured live CP epi-
thelial cells calculated from C (dashed line),
and measured in CP homogenates (solid line,
Œ), and in CP epithelial cell homogenates
(solid line, ) using the glutathione peroxi-
dase-specific enzymatic method. Km and
Vmax values are expressed in M and nmol·
min1·mg protein1, respectively. CP, cho-
roid plexus; CPEC, choroid plexus epithelial
cells; CSF, cerebrospinal fluid; GPxs, gluta-
thione peroxidases.
Table 3. Absence of H2O2 inactivation by choroid plexus
epithelial cell conditioned media
Time, min
0 7.5 25
H2O2 concentration, %
Apical medium 100  3.5 nd 98.0  2.3
Basolateral medium 100  3.5 106.5  2.9 104.8  3.2
Data are expressed as percentage of the H2O2 concentration measured
following incubation in non cell-exposed Ringer HEPES buffer (means  SD,
n 
 4). Ringer HEPES buffer was collected from either the apical or the
basolateral compartments 7.5 and 25 min after addition onto choroidal epithe-
lial cells grown in a two-chamber device. Hydrogen peroxide (44 M) was
added to either conditioned medium for a period equivalent to the conditioning
period. nd, Not determined.
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below 250 M. The constant Vmax-to-Km ratio, an index of the
catalytic efficiency, generated by these data for catalase, is
0.163 ml·min1·mg protein1. The kinetic parameters Km and
Vmax determined for GPx-dependent H2O2 inactivation in live
cultured choroidal cells were 272.7 M and 88.5 nmol·
min1·mg protein1, respectively. The Hanes-Woolf represen-
tation of GPx kinetic is reported in Fig. 4D (dashed line). The
kinetic parameters measured in CP homogenates using the
GPx-specific enzymatic method were 10.3 M for Km and
116.3 nmol·min1·mg protein1 for Vmax (Fig. 4D, solid line,
triangle). The large difference in Km values between the two
experimental settings may be accounted for by a change in GPx
affinity for H2O2 induced by cell culture, or a reduced H2O2
accessibility in live cells compared with the homogenate. To
address this point, GPx kinetic parameters were measured in
homogenized cultured cells, in conditions where cell mem-
branes are disrupted. The Km of 7.9 M in homogenized
cultured cells (Fig. 4D, solid line, square) was similar to that of
CP homogenates, indicating that substrate accessibility rather
than enzymatic activity is the limiting parameter in H2O2
elimination by choroidal GPxs. The somewhat higher Vmax
(232.6 nmol·min1·mg protein1) measured in cultured CP
epithelial cell homogenates by comparison with CP homoge-
nates (Fig. 4D) could be attributed to the low GPx-active
stromal and vascular materiel present in whole CP homoge-
nates.
The major contribution of GPx activity in H2O2 detoxifica-
tion was confirmed in CP epithelial cells treated with 3-AT and
CDNB, which are respective inhibitors of catalase and GPxs
(Fig. 5A). Catalase inhibition had no effect on the clearance of
H2O2 elimination while GPx inhibition resulted in a substantial
decrease in this parameter. Treatment with both inhibitors
almost fully abolished H2O2 detoxification. The latter result
confirms that 3-AT efficiently inhibits catalase in our experi-
mental conditions and suggests that, when used alone, the
inhibitory effect of 3-AT on catalase is masked by the potent
compensating GPx detoxifying activity.
The choroid plexus epithelial cells form a metabolic barrier
preventing blood-borne H2O2 from reaching the cerebrospinal
fluid. Choroid plexus epithelial cells impeded the basolateral to
apical flux of H2O2 added at a 50 M concentration into the
blood compartment (Fig. 5B, Ctrl). The permeability coeffi-
cient Pt was inferior to 0.1 l·min1·cm2, a value set by the
detection limit of the H2O2 quantification technique in our
experimental conditions. Catalase inhibition had only a very
limited effect on H2O2 permeability, which became barely
measurable in the apical chamber (Fig. 5B; 3-AT). By contrast,
the choroidal permeability to H2O2 significantly increased
when GPx activity was inhibited (Fig. 5B, CDNB). Permea-
bility to H2O2 was further increased when cells were simulta-
neously treated with GPx and catalase inhibitors (Fig. 5B,
CDNB  3-AT). It became close to the permeability coeffi-
cient measured on filters coated with laminin without cells,
which was 12.5  0.5 l·min1·cm2 (mean  SE, n 
 3).
This demonstrates that choroidal GPxs play a crucial role in
providing a barrier function toward blood-borne H2O2.
The effect of these inhibiting conditions on the barrier
integrity was evaluated in a separate experiment, by measuring
the permeability of CP epithelial cells to sucrose, a small polar
nonpermeable marker (Fig. 5C). Both CDNB alone and a
combination of CDNB and 3-AT significantly increased su-
crose permeability in the presence of H2O2, while 3-AT alone
had no effect. The increase in permeability was already ob-
served at 20 min and was thereafter cumulative. The compound
CDNB per se does not impair the choroidal barrier function
when applied in the absence of H2O2 over a 60-min period
(25). The present data indicate that a few tens of micromolar
H2O2 has the intrinsic capacity to alter the integrity of the
blood-CSF barrier, and that choroidal GPxs are important to
protect the blood-CSF barrier from blood-borne hydroperox-
ides.
DISCUSSION
In this article, we showed that throughout postnatal devel-
opment, the CPs displayed a high GPx activity in comparison
to the neuropil. Western blotting and immunohistochemical
studies highlighted the choroidal specific expression of GPx1
and GPx4 in newborn rats. Similar choroidal GPx activity
levels and GPx1 immunopositivity were previously described
in adult animals, respectively in rat and mouse (60, 62). The
high GPx expression and functionality observed during early
postnatal development is an indicator of the early developmen-
tal maturation of the choroidal tissue. The GPx activity in CPs
was even higher than in liver at the early postnatal stages. This
has been reported previously for other detoxifying systems of
the CPs (40). It further sustains the concept that the choroidal
tissue is a distinctive neuroprotective brain structure during
postnatal development, when the liver is still immature in its
detoxifying function. These functions remain, however, highly
active throughout adulthood and in aging (60). Of note, the sex
difference in hepatic GPx activity observed in W5 and W12
rats (our data), and in mice (42, 59) does not exist in CPs.
A transcriptomic analysis of GPx isoenzymes in CPs of
developing as well as adult rats indicated that both GPx1 and
GPx4 genes are highly expressed by comparison to the other
isoenzymes GPx2 and GPx3 (39). Altogether, the transcrip-
tomic and immunohistological data point out GPx1 and GPx4
Table 4. H2O2 elimination half-life and elimination rate in choroid plexus epithelial cells
Initial [H2O2], M
Initial H2O2 Quantity,
mol/mg protein
Initial Elimination Rate
Constant kel, min1
Elimination Half-
Life t1/2, min
H2O2 Elimination Rate , nmol·min1·mg protein1
Total
First-Order Reaction
(Catalase)
Mixed-Order Reaction
(GPxs)
446.7  21.8 5.4  0.5 0.0241 28.8 127.6 72.79 54.80
205.4  16.3 1.9  0.1 0.0371 18.7 71.4 33.46 37.95
50.2  7.4 0.5  0.0 0.0459 15.1 21.9 8.18 13.75
20.8  0.7 0.2  0.0 0.0521 13.3 9.6 3.38 6.26
Initial H2O2 concentration and quantity are means  SE (n 
 3). GPxs, glutathione peroxidases. See MATERIALS AND METHODS for definition of H2O2
elimination parameters and details on calculations.
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isoenzymes as the main probable effectors of the high choroi-
dal GPx activity measured throughout development. Hydrogen
peroxide is a prototypic hydroperoxide substrate common to all
GPx isoenzymes (8). Glutathione peroxidase 1 can also accept
soluble low molecular mass hydroperoxides such as t-butyl
hydroperoxide as substrates (8). This isoenzyme seems to be
mainly involved in antioxidant defense, since GPx1-knockout
mice are highly sensitive to acute oxidative stress (11). Gluta-
thione peroxidase 4 is able to reduce both small hydroperox-
ides and more complex lipid hydroperoxides, including those
inserted in membranes. It is involved in various physiologic
processes, such as the control of apoptosis or leukotriene
synthesis by regulating the 12,15- and 5-lipoxygenase activi-
ties, respectively (8, 34). Hence, these two choroidal isoen-
zymes appear to have complementary functions, hinting at the
hypothesis that CPs are involved in both physiological signal-
ing and detoxification processes (see below). Besides GPxs and
catalase, peroxiredoxins also display a reductive activity to-
wards H2O2, but they are involved in cell redox sensing rather
than in hydroperoxide inactivation. They are unlikely to con-
tribute to the peroxidase activity we measured in CPs. This
activity was mainly GSH-dependent whereas peroxiredoxins
do not use GSH as a cosubstrate. In addition, the peroxiredoxin
catalytic constant is lower by three orders of magnitude than
that of GPxs (31, 51).
We demonstrated the functional relevance of the high cho-
roidal GPx expression by showing that live CPs have a rare
ability to detoxify H2O2, and GPxs are the main enzymes
involved in the process for hydroperoxide concentration up to
250 M. This specific feature of the CPs may serve several
purposes.
First, choroidal peroxidase activity can be related to self-
protection of the tissue. The metabolic activity and energy
demand of choroidal epithelial cells are high. This results from
the energy-consuming maintenance of a tight barrier between
the blood and the CSF. It also bears on other energy-consum-
ing mechanisms that include CSF secretion, the synthesis and
secretion of polypeptides involved in brain development and
neuroimmune regulation, and multiple ATP-dependent trans-
port processes (24). The corresponding high number of mito-
chondria in choroidal cells (12) calls for potent antioxidant
mechanisms to counteract superoxide and H2O2 molecules
generated by oxidative phosphorylation. This may account at
least partially for the high GPx activities associated with the
choroidal tissue. Exposure of choroidal epithelial cells to high
levels of H2O2 (65), or to a moderate level of the hydroperox-
ide in the presence of a GPx inhibitor (our data) induces an
alteration of the tightness of the blood-CSF barrier. Controlling
H2O2 concentration in choroidal epithelial cells is thus essen-
tial to maintain the integrity of the blood-CSF barrier. Choroi-
Fig. 5. Effect of catalase and glutathione peroxidase inhibition on H2O2
elimination, permeation, and toxicity on the blood-cerebrospinal fluid barrier.
After preincubation with 50 M CDNB, 10 mM 3-AT, or both, choroid plexus
epithelial cells were basolaterally exposed to 50 M H2O2 in the presence of
the inhibitors. The apical and basolateral compartments were sampled sepa-
rately after 20 min and assayed for H2O2. A: amount of H2O2 eliminated after
20 min. Data are expressed as H2O2 clearance volume (means  SD; n 
 4).
Statistical differences from control value: ***P  0.001, one-way ANOVA
with Dunnett’s multiple comparisons test. B: basolateral to apical flux of H2O2
during the 20-min incubation period. Data are expressed as permeability
constant, Pt (means  SD, n 
 4). Statistical differences from CDNB condi-
tion: ***P  0.001 one-way ANOVA with Dunnett’s multiple comparisons
test. C: evaluation of the barrier integrity. Cells were pretreated as in A and
exposed to [14C]sucrose at the time of H2O2 addition. The basolateral to apical
flux of sucrose was measured during three consecutive periods. Data are
expressed as cumulated sucrose clearance (means  SD, n 
 3). Statistical
differences from control value for each period of time: ***P  0.001, two-way
ANOVA with Dunnett’s multiple comparisons test. CDNB, 1-chloro-2,4-
dinitrobenzene; CP, choroid plexus; Ctrl, control; 3-AT, 3-aminotriazole.
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dal GPxs should also prevent the propagation of lipid peroxi-
dation in CP epithelial cells and the subsequent formation of
toxic by-products induced by supraphysiological levels of lipid
hydroperoxides (3).
Second, the strong hydroperoxide inactivation capacity of
the choroidal tissue can also participate to the signal termina-
tion of H2O2 and lipid hydroperoxides released in nonpatho-
logical conditions. During brain development, H2O2 acts as an
intra- and intercellular signaling mediator involved in cell
development and proliferation, axonal guidance, GABAergic
synaptic transmission, and cell death regulation through the
control of cell redox processes (2, 7, 20, 52). Diffusion or
drainage of hydroperoxides into the CSF from the connected
interstitial fluid, coupled to their inactivation by the lateral and
4th ventricle CPs, may participate in controlling their extracel-
lular levels. This choroidal function may be essential as glial
cell reductive capacities are not fully functional during brain
development, and the relative volume occupied by CSF in the
cranial cavity is high (22).
Third, the GPx-dependent capacity of CPs to inactivate
hydroperoxides represents a powerful mechanism of neuropro-
tection against central oxidative stress, a common determinant
in oxidative, inflammatory, infectious, or toxic insults. The
noxious effects that supraphysiological H2O2 concentrations in
cerebral fluid can exert on brain development are sustained in
various pathologies. Down syndrome patients suffer early on
from excessive oxidative stress related to an increased produc-
tion of H2O2 as a result of an elevated superoxide dismutase
activity (46). In asphyxiated newborns, encephalopathy occur-
rence is correlated with an elevated level of total hydroperox-
ides in CSF (32). The levels of ROS, including H2O2, are
elevated in the CSF in neonates and children diagnosed with
acute bacterial meningitis, and these H2O2 levels in CSF are
significantly higher in patients with neurological sequelae
compared with patients that recover (36). Hydrogen peroxide
generated in the course of bacterial infection can also trigger
alterations in the ependyma bordering the cerebral ventricles,
including an inhibition of ciliary activity (30). This may affect
the maturation of the ventricular system and be deleterious to
the neural progenitors that are present in the subependymal
areas and contribute to gliogenesis and neurogenesis during
development. By reducing H2O2 concentration in brain fluids
below toxic levels, CPs will contribute to limit H2O2-induced
brain damage induced by inflammation, infection, hypoxia, or
drug exposure during the peri/postnatal period.
Few studies have been aimed at estimating the concentration
of H2O2 released in brain fluids during such oxidative, inflam-
matory, or infectious stresses. In vivo microdialysis in the
striatum has been performed to measure H2O2 levels during
and after an ischemia-reperfusion event in adult rat (33). The
concentration increased from 20 to 70–120 M after 30 min of
reperfusion that followed a 30-min ischemia. A similar study
conducted on adult gerbils showed an increase from 1–2 to 3–4
M after a 5-min ischemia followed by 10 min of reperfusion
(41). In human, H2O2 levels in CSF measured in the course of
pediatric diseases are in the order of several tens of micromoles
(36). This limited set of data suggests that the H2O2 concen-
tration range for which choroidal GPxs are the most efficient
(below 250 M) is relevant to the pathophysiological H2O2
levels released in brain fluids during postnatal insults. The
concentration threshold above which H2O2 becomes toxic in
vivo has not been established either. While H2O2 concentra-
tions in the 50 M range are toxic to neural cells in vitro (28),
H2O2-mediated neurotoxic effects are likely to arise at lower
concentrations in vivo owing to the generation of the hydroxyl
radical (·OH). This highly reactive free radical is formed by the
nonenzymatic Fenton reaction which can occur in the CSF
(55). Finally, small amounts of H2O2 circulate in the blood (19,
29), and various peripheral stresses increase hydroperoxide
levels in plasma. Infants with sepsis present blood levels of
H2O2 around 35 M, which is more than six times higher than
the concentration in healthy infants (48). We showed that the
choroidal epithelium acts as an enzymatic barrier preventing
blood-borne H2O2 from reaching the CSF and brain. This
barrier effect will be especially crucial during development, as
the CPs are then a quantitatively important gate of entry in the
brain for molecules circulating in blood (23).
The analysis of GPx kinetic parameters in live cells and in
homogenates indicates that CP epithelial membrane permea-
bility to H2O2 is the limiting step in GPx-dependent H2O2
detoxification. The mechanism by which H2O2 crosses the
epithelial cell membrane remains to be ascertained. Besides
simple diffusion, extracellular H2O2 can get access to the
intracellular compartment through diffusion-facilitating chan-
nel proteins from the aquaporin superfamily, including aqua-
porin 1 (6, 7). This channel participates in water transport
during CSF secretion (50). Aquaporin 1 is predominantly
localized in the apical membrane domain of choroidal epithe-
lial cells, and to some degree in their basolateral membrane
domain (50). We observed no difference in the rate of H2O2
degradation between the apical and basolateral exposure con-
ditions. This suggests that diffusion rather than aquaporin
1-dependent transfer drives H2O2 access to intracellular GPxs.
In conclusion, this work identified the CPs as a major site of
hydroperoxide inactivation in the brain during the postnatal
period and showed that GPxs are the main enzymes responsible
for this inactivation. The high choroidal peroxidase capacity
represents an additional component of the detoxifying machin-
ery functioning in CPs during brain development, and it should
be especially relevant to the inactivation of supraphysiological
toxic levels of hydroperoxides generated during peri/postnatal
insults. In addition, choroidal GPxs should be essential to
maintain the integrity of the blood-CSF barrier itself, by
detoxifying reactive species arising from the basal metabolism
of this highly energetic interface or from oxidative injuries.
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Cellular/Molecular
Glutathione Conjugation at the Blood–CSF Barrier Efficiently
Prevents Exposure of the Developing Brain Fluid Environment
to Blood-Borne Reactive Electrophilic Substances
X Ingrid Kratzer,1* Nathalie Strazielle,1,2,3* Elodie Saudrais,1,3 Kati Mönkkönen,1 Céline Malleval,1 Sandrine Blondel,3
and Jean-François Ghersi-Egea1,3
1FLUID Team, Lyon Neurosciences Research Center, INSERM U1028 CNRS UMR 5292, Université Claude Bernard Lyon-1, 69008 Lyon, France, 2Brain-i,
69008 Lyon, France, and 3Blood-Brain Interfaces Exploratory Platform BIP, Lyon Neurosciences Research Center, 69008 Lyon, France
Exposure of the developing brain to toxins, drugs, or deleterious endogenous compounds during the perinatal period can trigger
alterations in cell division, migration, differentiation, and synaptogenesis, leading to lifelong neurological impairment. The brain is
protected by cellular barriers acting through multiple mechanisms, some of which are still poorly explored. We used a combination of
enzymatic assays, live tissue fluorescence microscopy, and an in vitro cellular model of the blood–CSF barrier to investigate an enzymatic
detoxification pathway in the developing male and female rat brain. We show that during the early postnatal period the choroid plexus
epithelium forming the blood–CSF barrier and the ependymal cell layer bordering the ventricles harbor a high detoxifying capacity that
involves glutathione S-transferases. Using a functional knock-down rat model for choroidal glutathione conjugation, we demonstrate that
already in neonates, this metabolic pathway efficiently prevents the penetration of blood-borne reactive compounds into CSF. The versatility of
the protective mechanism results from the multiplicity of the glutathione S-transferase isoenzymes, which are differently expressed between the
choroidal epithelium and the ependyma. The various isoenzymes display differential substrate specificities, which greatly widen the spectrum of
molecules that can be inactivated by this pathway. In conclusion, the blood–CSF barrier and the ependyma are identified as key cellular
structures in the CNS to protect the brain fluid environment from different chemical classes of potentially toxic compounds during the postnatal
period. This metabolic neuroprotective function of brain interfaces ought to compensate for the liver postnatal immaturity.
Key words: blood– brain barriers; brain homeostasis; glutathione S-transferases; neuroprotection; oxidative stress; perinatal
Introduction
The developing brain is sensitive to chemical insults and oxida-
tive stress, and the resulting damage can be devastating, resulting
in lifelong neurological impairment (Dammann and Leviton,
1999; Favrais et al., 2011). The blood– brain interfaces, namely
the blood– brain barrier located at the endothelium of the cere-
bral microvessels and the blood–CSF barrier located at the epi-
thelium of the choroid plexuses efficiently protect the adult brain
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Significance Statement
Brain homeostasis requires a stable and controlled internal environment. Defective brain protection during the perinatal period
can lead to lifelong neurological impairment. We demonstrate that the choroid plexus forming the blood–CSF barrier is a key
player in the protection of the developing brain. Glutathione-dependent enzymatic metabolism in the choroidal epithelium
inactivates a broad spectrum of noxious compounds, efficiently preventing their penetration into the CSF. A second line of
detoxification is located in the ependyma separating the CSF from brain tissue. Our study reveals a novel facet of the mechanisms
by which the brain is protected at a period of high vulnerability, at a time when the astrocytic network is still immature and liver
xenobiotic metabolism is limited.
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from circulating toxic substances by a set of mechanisms com-
bining tight junctions, efflux transporters, and detoxifying en-
zymes (Neuwelt et al., 2008; Strazielle and Ghersi-Egea, 2013;
Ghersi-Egea et al., 2018). These interfaces have often been con-
sidered functionally immature during prenatal and postnatal de-
velopment, thereby contributing to the vulnerability of the
maturing brain. This concept of barrier immaturity is being chal-
lenged. The efficacy of tight junctions, which link neighboring
barrier cells together, in preventing paracellular diffusion during
development has been demonstrated (Johansson et al., 2006).
This efficacy results from the early expression and correct mem-
brane localization of the multiple proteins forming these tight
junctions in both rat and human brain barrier cells (Kratzer et al.,
2012). The functionality of transport and metabolic processes
during the perinatal period remains largely unaddressed (Stra-
zielle and Ghersi-Egea, 2015). Glutathione S-transferases (GSTs)
form a family of isoenzymes largely involved in detoxification
processes (Hayes et al., 2005). Several immunohistochemical
analyses have pointed out an apparently robust expression of
GSTs in the choroid plexuses and ependyma (for review, see Stra-
zielle et al., 2004). A high enzymatic activity of conjugation to
reduced glutathione (GSH) has been measured in homogenates
of choroid plexuses isolated from both fetal human and postnatal
rat brains (Ghersi-Egea et al., 2006). More recently, a transcriptomic
analysis of choroid plexus identified several GST isoenzymes that are
expressed during development (Kratzer et al., 2013), revealing
perinatal-specific detoxification properties of the blood–CSF
barrier. The detoxification properties of this tissue may therefore
be especially crucial in protecting the brain during the perinatal
period when the CSF, in which the brain develops, represents a
large proportion of the cerebral extracellular fluid (Ghersi-Egea
et al., 2015).
In this work, we identify the choroid plexuses and the ependyma
as major sites for GSH conjugation in the developing brain. We
provide the in vivo demonstration that choroidal GSTs support a
metabolic barrier function of the blood–CSF interface protecting
the maturing brain, by preventing the penetration of blood-
borne electrophilic substrates into the CSF. We finally provide
the molecular identity and relative level of expression of the dif-
ferent GST isoenzymes responsible for neuroprotection at the
blood–CSF barrier and ependyma.
Materials and Methods
Animals, tissue sampling, and processing. Female OFA rats with their litter,
and 35-day-old [postnatal day 35 (P35)] and 200 g adult male OFA rats
were obtained from Janvier. Animal care and procedures were conducted
according to the guidelines approved by the French Ethical Committee
(decree 87-848) and by European Community directive 86-609-EEC.
The ethical committee for animal experimentation CEEA-55 has ap-
proved the present research project. All animals were kept under identi-
cal conditions in standard cages, with free access to food and tap water
under a controlled environment (12 h dark/light cycles). Animals were
killed at different postnatal ages by decapitation following deep iso-
flurane gas anesthesia. Following brain extraction in Ca- and Mg-
supplemented PBS, lateral ventricle and fourth ventricle choroid
plexuses and cerebral cortices devoid of meninges were sampled under a
stereomicroscope at 4°C. Tissues were frozen and kept at 80°C for
enzymatic analysis or RNA isolation. Alternatively, some brains were
either collected in ice-cold Krebs-Ringer (KR) buffer (135 mM NaCl, 4
mM KCl, 2.2 mM CaCl2, 1.2 mM MgCl2, 6 mM NaHCO3, 10 mM HEPES,
and 5 mM glucose, pH 7.4) and immediately sliced for imaging studies, or
were frozen in 40°C cold isopentane and kept at 80°C until used for
laser microdissection. In some animals, the liver was also sampled.
Choroidal glutathione-depleted animals. Two-day-old rat pups were
treated with DL-buthionine-(S,R)-sulfoximine (BSO; catalog B2640,
Sigma-Aldrich) to generate developing animals that display a severe
(92%) GSH depletion in blood–CSF barrier cells. The pups were treated
by three intraperitoneal injections of 2 	mol/g depleting agent in di-
methylsulfoxide/NaCl 0.9% (15/85), performed on 2 consecutive days
(9:00 A.M. and 4:00 P.M. on P2, and 9:00 A.M. on the following day).
Half of the litter was treated with BSO, and the second half was treated
with vehicle only. Animals were used for permeability measurement 4 h
after the last injection (see Fig. 3).
Glutathione S-transferase activity measurement. Choroidal tissue, cere-
bral cortices, and liver were sampled from P2, P7, P35, and adult rats.
Tissues were homogenized in a 0.25 M sucrose, 50 mM K-phosphate, 1 mM
K-EDTA, and 0.1 mM dithiothreitol buffer, pH 7.4, using a Tenbroeck
homogenizer. Glutathione S-transferase activity was determined by a 15
min kinetic analysis in a M200 Pro TECAN plate spectrofluorimeter.
Assays were conducted in 250 	l of 0.05 M K-phosphate and 0.02%
bovine serum albumin, pH 6.5 at 22°C, using 1 mM GSH (Sigma-
Aldrich), and 50 	M monochlorobimane (MCB; Sigma-Aldrich) as a
substrate. Excitation and emission wavelengths of 355 and 460 nm, re-
spectively, were used to detect and quantify the rate of appearance of the
GSH conjugate GS-MCB. The low rate of nonenzymatic conjugation of
MCB to GSH was assessed by omitting the protein homogenate from the
complete assay mixture. Production of the conjugate was calibrated in
each sample by measuring the increase in fluorescence intensity pro-
duced by the addition of 1 nmol of pure GS-MCB at the end of the kinetic
analysis. The specific activity was then expressed as nanomoles of conju-
gate produced per minute and per milligrams of proteins. The total pro-
tein content of the samples was determined by the method of Peterson
(1977) with bovine serum albumin as the standard. The GS-MCB used as
a calibrator was prepared and purified as follows. Known concentrations
of MCB were incubated with rat liver homogenate and GSH in excess in
a 37°C water bath for 20 min to produce GS-MCB. Final concentration of
the standard was calculated after determining the presence of residual
unconjugated MCB by HPLC, as previously described for another con-
jugate (Ghersi-Egea et al., 2006).
For in vitro competition studies, GST activity was measured toward
1-chloro-2,4-dinitrobenzene (CDNB) in the presence of 1 mM GSH and
50 or 200 	M competitor. These competitor concentrations were about
twofold and eightfold higher than the apparent affinity constant for
CDNB in choroidal tissue. Production of the conjugate was followed at
340 nm by kinetic spectrophotometry, as previously described (Ghersi-
Egea et al., 2006). All the potential competitive substrates were tested for
their limited absorbance at 340 nm.
Imaging of GSH conjugation in ependyma-containing brain slices and
isolated choroid plexuses. Brains of P6 animals were dissected under a
stereomicroscope in ice-cold KR buffer to isolate the midbrain tissue.
The latter was sliced in ice-cold KR buffer using a McIllwain tissue chop-
per to generate 200-	m-thick ependyma-containing brain slices. Freshly
cut brain slices were warmed to 22°C in a few microliters of buffer on a
glass slide under a Zeiss AxioPlan 2 Microscope, equipped with the Dig-
ital Camera F-View II and AnalySISauto software (Olympus Soft Imag-
ing Solutions). Fluorescence images were recorded at 460 nm with a 390
nm excitation beam switched on only intermittently. This protocol pre-
vented photobleaching, the acute cellular toxicity induced by UV waves,
and the depletion of the cellular pool of ATP that is necessary for trans-
port processes. An initial image was recorded in the ependymal area
(negative control). Buffer was removed and replaced with a 10 	M MCB
solution, and fluorescence images were again recorded 0.7 and 4 min
after MCB addition. All images were recorded with the same time expo-
sure. On each recorded image, a fluorescence intensity profile was estab-
lished along a rectangle perpendicular to the ependymal cell layer using
ImageJ software. This yielded average fluorescence intensity data in both
the ependyma and in the adjacent tissue.
For fluorescence image recording on choroid plexus, the choroidal
tissue was rapidly dissected from the brain of P5 animals in ice-cold KR
buffer, transferred on a glass slide in a few microliters of buffer, main-
tained with a 300 	m mesh sieve, and allowed to warm up at 22°C before
MCB addition and image recording, as described above.
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Intracerebroventricular monochlorobimane injection and imaging of
GSH conjugation. P4 rats were set in a stereotaxic frame under inhaled
anesthesia (4 –5% isoflurane, 60%/40% O2/air), associated with a local
topical application of lidocaine/prilocaine (Anesderm, Pierre Fabre).
Two microliters of artificial CSF (124 mM NaCl, 2.5 mM KCl, 2.5 mM
CaCl2, 1.3 mM MgCl2, 26 mM NaHCO3, 1.25 mM Na2HPO4, and 10 mM
glucose, pH 7.3) containing 0.7% EtOH and 200 	M MCB were injected
over 10 s in the lateral ventricle using a 30 gauge needle. Stereotaxic
coordinates relative to 
 were 4 mm anteroposterior, 1.2 mm lateral,
and 2.4 mm dorsoventral. The needle was removed 50 s after the end of
the injection, and the head of the anesthetized animal was immediately
severed and frozen in 40°C isopentane. The head was then sliced in a
cryostat as previously described (Ghersi-Egea et al., 2015), and 20-	m-
thick coronal sections were dried immediately on a plate heater set at
37°C. Fluorescence images were instantly recorded using the Zeiss
AxioPlan 2 Microscope.
Primary culture of choroidal epithelial cells. Primary cultures of choroid
plexus epithelial cells were prepared from neonate rat choroid plexuses,
as previously described (Strazielle and Ghersi-Egea, 1999; Strazielle et al.,
2003). The cells were seeded on microporous Transwell polycarbonate
filter inserts (either 0.33 or 1.12 cm 2 surface area, and 0.4 	m pore size;
Corning Life Sciences) and grown in culture medium consisting of
Ham’s F-12 medium and DMEM (1:1) supplemented with 10% FCS, 2
mM glutamine, 50 mg/ml gentamicin, and several growth factors, as pre-
viously reported (Strazielle and Ghersi-Egea, 1999). The medium was
renewed every other day until the permeability studies, which were per-
formed 5 d after cells reached confluence.
In vitro cellular permeability and metabolic studies. Permeability and
metabolic studies were performed on a rotating shaker (300 rpm) at
37°C, in Ringer-HEPES buffer (RH; 150 mM NaCl, 5.2 mM KCl, 2.2 mM
CaCl2, 0.2 mM MgCl2, 6 mM NaHCO3, 2.8 mM glucose, and 5 mM HEPES,
pH 7.4). The volumes used in the two compartments of the inserts (the
bottom basolateral one mimicking blood, and the top apical one mim-
icking CSF) were selected as to be in equilibrium to prevent any hydro-
static pressure effect. Inserts were rinsed once with RH buffer before
initiating the transport studies. MCB was added to the basolateral com-
partment at a concentration of 5 or 50 	M. At regular time intervals, the
inserts were transferred into another well containing fresh incubation
solution, and four-fifths of the volume in the apical compartment was
sampled and replaced with fresh prewarmed RH. Media from the apical
and basolateral compartments were analyzed by spectrofluorimetry (ex-
citation/emission at 355/460 nm) for GS-MCB and by HPLC for MCB.
The organic anion transporter inhibitor probenecid was used at a con-
centration of 3 mM in both compartments. It was added 30 min before
incubating the cells with MCB, and was kept and renewed in both
compartments following each sampling. Monochlorobimane clearance
volumes were calculated for each time interval, taking into account the
residual volume remaining in the apical compartment from the previous
time point, as previously described (Strazielle and Preston, 2003). For
quantification of spectrofluorimetric data, the GS-MCB calibrator de-
scribed above for enzymatic measurement was used. Experiments were
run in parallel using cell-covered filters in the absence of MCB, with and
without probenecid, to measure the background fluorescence levels as-
sociated with the inhibitor or any solute secreted by the epithelial cells
during the transfer experiment. Background fluorescence was subtracted
from the total fluorescence before calculating the amount of GS-MCB
released by the cells in both compartments. The intracellular GS-MCB
content was assessed as follows: inserts were rinsed twice for 5 min in RH
buffer at 4°C on an orbital shaker; the cell-covered filters were quickly
detached from their plastic support and stored at 20°C in 100 	l of
water/ethanol (98/2 v/v) containing 250 	M ethacrynic acid. After thaw-
ing and homogenization by trituration using a conic plastic pestle, an
aliquot of the liquid was analyzed by spectrofluorimetry as described
above. Ethacrynic acid was added to the medium to prevent further
conjugation of residual MCB to GSH during cell homogenization.
To assess the innocuousness of the different compounds and vehicles
added on the epithelial cell layer, [14C]-sucrose permeability was mea-
sured as an index of barrier integrity. Data were expressed as permeability
coefficients Pe (in centimeters per minute) calculated from the clearance
curves generated as previously described in detail (Strazielle and Ghersi-
Egea, 1999; Strazielle et al., 2003). Radioactivity was determined by liquid
scintillation counting using a -counter (Tri-Carb 1600 TR, Canberra
Packard).
In vivo blood–CSF transport studies. The permeability of the blood–
CSF barrier to CDNB was measured in BSO-treated and untreated ani-
mals by perfusing the compound into the vascular system through the
heart and sampling CSF. Animals were anesthetized with pentobarbital
(5 	l/g), and the heart was exposed. Intracardiac perfusion of a physio-
logical buffer (128 mM NaCl, 2 mM NaHCO3, 4.2 mM KCl, 2.4 mM
NaH2PO4, 1.5 mM CaCl2, 0.9 mM MgSO4, and 9 mM D-glucose) was
performed at a physiological rate (0.67 ml/min) for 2 min using a dual-
perfusion pump (AL-1000, WPI). This was followed by a 5 min perfusion
of the same buffer supplemented with CDNB at various concentrations.
This cardiac perfusion protocol did not alter the choroid plexus mor-
phology, as assessed by hematoxylin and phloxin histology staining and
claudin-1 immunolabeling of sections of brains sampled after perfusion
(data not shown). After the perfusion was stopped, the animal was turned
over and the skin over the cistern magna was quickly excised. CSF (4 – 8
	l) was sampled using a glass microcapillary sampler with an outer tip
diameter of 500 	m. CSF volume was precisely measured. CSF was
then mixed with acetonitrile/H2O (50/50) to reach a total volume of 40 	l
and analyzed by HPLC for its CDNB content. The blood–CSF barrier
integrity in control and BSO-treated animals was assessed by measuring
the Kin csf permeability constant for [
14C]-sucrose as previously de-
scribed (Ghersi-Egea et al., 2015). The apparent blood– cerebral cortex
permeability constant AppKin Cx for [
14C]-sucrose was measured in a
similar way, without correcting for the amount of sucrose associated with
the tissue for the residual vascular content.
Quantification of monocholorobimane, 1-chloro-2,4-dinitrobenzene,
and reduced glutathione. A Shimadzu LC10 HPLC System was used.
Monochlorobimane was quantified using UV detection at 236 nm. CSF,
buffers, and media were directly injected on a 150 mm hypersil 5 	m C18
BDS column (Thouzart and Matignon), and the compound was eluted
using an isocratic 20/80 acetonitrile/water mobile phase at a 1 ml/min
flow rate. The monochlorobimane retention time was 8 min. 1-Chloro-
2,4-dinitrobenzene was quantified on an Ultraphere ODS RP-18 Analyt-
ical Column (Beckman) using an isocratic 55/10/35 methanol/10 mM
phosphate buffer pH 6/water mobile phase at a 1 ml/min flow rate. It was
detected at 250 nm with a retention time of 11 min. Reduced glutathione
was coupled with 5,5-dithio-bis(2-nitrobenzoic) acid in 10 mM phos-
phate buffer, pH 7.4, and analyzed on the Ultrasphere ODS RP-18 col-
umn, using a methanol/phosphate buffer elution gradient as previously
described (Schmitt et al., 2011). UV detection was set at 324 nm, and the
retention time was 6.6 min. For all compounds, the area under the curve
of the peak of interest was measured, and quantification was performed
using a calibration curve generated from standard solutions.
Total RNA extraction, reverse transcription, and real-time PCR. Liver,
choroid plexuses from lateral and fourth ventricles, and cerebral cortex
from P2, P10, and adult Sprague Dawley rats were sampled. When col-
lected from P2 and P10 pups, choroid plexuses were pooled from three to
four animals. For comparative purpose, RNA was also extracted from
two batches of microvessels prepared from P9 and adult rat brain, as
described previously in detail (Gazzin et al., 2008). Total RNA was ex-
tracted using RNeasy Mini (liver) or Micro (choroid plexuses, cortex,
and capillaries) kits (Qiagen) according to the manufacturer instruc-
tions. Before RNA extraction, liver, cerebral cortex, and capillaries were
homogenized in the RLT buffer using a FastPrep shaker (QBiogene).
Capillary homogenates were treated with Proteinase K (Qiagen) at 55°C
for 10 min. Choroid plexus tissues from lateral and fourth ventricles were
dissociated by pipetting. All samples were treated on column with DNase
I as recommended by the manufacturer. RNA was quantified using a
NanoDrop spectrophotometer (Thermo Fisher Scientific), and RNA in-
tegrity was assessed using the Agilent 2100 Bioanalyzer.
RNA was reverse transcribed using oligo(dT) primers and the Verso
SYBR Green 2-step RT-qPCR Rox Kit (Thermo Fisher Scientific). Total
RNA (1 	g) was spiked with 50 pg of AraB RNA (L-ribulokinase, E. coli
strain K-12, substrain MG1655, GE Healthcare Bio-Sciences). The bac-
terial RNA was added in each reaction mixture as an external standard for
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normalization. Reverse transcription was run at 42°C for 60 min. Quan-
titative PCR (qPCR) was performed using the FastStart DNA Master
SYBR Green I Kit in the LightCycler 1.5 instrument (Roche Applied
Science), as previously described (Kratzer et al., 2012). Primer sequences,
MgCl2 concentrations, and sizes of the predicted amplicons are pre-
sented in Table 1. Results were analyzed using RelQuant 1.01 software
(Roche Applied Science), which takes into account the respective ampli-
fication efficiencies of the target gene and the external standard (AraB)
when calculating the target gene/standard ratio. An approximate ranking
of abundance of the different GST gene products was generated first by
establishing the expression levels of all genes in a reference sample, arbi-
trarily chosen as adult liver N°2, and second by calculating for each target
gene the expression levels in all individual samples relative to the value in
the reference sample, as previously described (Kratzer et al., 2012).
Ependyma laser microdissection and sample processing. Brains were dis-
sected from P2, P9, and adult Sprague Dawley rats. Twelve-micrometer-
thick sections were cut around bregma using a Shandon Cryotome E
(Thermo Fisher Scientific) in an RNase-free environment, rapidly air
dried, frozen on dry ice, and kept at 80°C until further processed for
laser microdissection. Sections were thawed and stained using the
Ambion LCM Staining Kit (Thermo Fisher Scientific), according to the
manufacturer instructions. Briefly, sections were fixed in 95% ethanol,
rehydrated into 75% and 50% ethanol, and stained in cresyl violet. They
were dehydrated in 75% to 100% ethanol solutions, then in xylene and
kept in a vacuum chamber with dessicant until used to perform micro-
dissection. The PixCell II laser capture microdissection instrument (Arc-
turus Engineering) was used to isolate the ependymal layer of the lateral
ventricle wall and adjacent caudate–putamen tissue (see Fig. 8). The
captured tissue was lysed in RLT buffer and RNA was extracted and
treated with DNase I using the RNeasy Micro Kit, as described above.
RNA integrity was assessed using the Agilent 2100 Bioanalyzer and RNA
was quantified using the Quant-iT RiboGreen Reagent (Thermo Fisher
Scientific). RNA samples (5 ng) were spiked with 0.125 pg of bacterial
AraB RNA. Two amplification rounds were performed using the Expres-
sArt NANO RNA Linear Amplification Kit (amsbio). The quality of am-
plified RNA was assessed using the Agilent 2100 Bioanalyzer, and reverse
transcription of 1 	g of RNA was performed using the iScript Reverse
Transcription Supermix for RT-qPCR (Bio-Rad). Real-time PCR was
performed as described above.
Western blot analysis. Western blot analysis of GSTs in tissue sampled
from P2 or P9 rats was performed using anti-GST3 rabbit polyclonal
antibody (pAb; MBS713631, MyBioSource), anti-GST	1/2 rabbit mono-
clonal Ab (ab108524, Abcam), anti-GST	5 rabbit pAb (MBS712299, My-
BioSource), and anti-GST1 rabbit pAb (PAB13020, Abnova). Actin
used as a loading control was detected with anti--actin mouse mono-
clonal Ab (A1978, Sigma-Aldrich). Proteins were separated on 10% Bis-
Tris Criterion XT Gels (Bio-Rad) run in MOPS [3-(N-morpholino)
propanesulfonic acid] buffer (Bio-Rad) at 70 V for 10 min, followed by
120 V for 2 h. The gel was blotted onto 0.2 	m Protran nitrocellulose
membrane (GE Healthcare Life Sciences) in Tris-glycine transfer buffer
(Euromedex) containing 20% methanol for 50 min at 100 V. The mem-
brane was saturated in 5% skimmed milk, 0.1% Tween 20 in Tris-
buffered saline (TBS) at room temperature for 1 h. Primary anti-GST
antibodies were diluted in saturation buffer at 0.69 	g/ml for
GST	1/2, 0.7 	g/ml for GST	5, 1 	g/ml for GST1, and 0.31 	g/ml for
GST3. The anti--actin mouse Ab was used at a final dilution of either
0.1 or 0.05 	g/ml, depending on the amount of protein loaded. Mem-
branes were incubated at 4°C overnight, then washed three times for 10
min in TBS containing 0.1% Tween-20 (TBS-T) at room temperature.
Horseradish peroxidase (HRP)-conjugated secondary antibodies were
from Jackson ImmunoResearch. Donkey anti-rabbit IgG pAb (711-036-
152) was used at a final concentration of 0.04 	g/ml for GST3, GST1,
and GST	1/2, and 0.08 	g/ml for GST	5, and donkey anti-mouse IgG
pAb (catalog #715-036-151, Jackson ImmunoResearch) was used at a
final concentration of 0.04 	g/ml. After two washes in TBS-T and a final
one in TBS, chemiluminescent HRP substrate (SuperSignal West Pico
Chemiluminescent Substrate, Thermo Fisher Scientific) was used and
membranes were exposed to x-ray films (Hyperfilm ECL, GE Healthcare
Life Sciences). Only one band was observed for GST	1/2 (28 kDa),
GST	5 (26 kDa), GST3 (26 kDa), and GST1 (24 kDa) in postnatal
choroid plexus. Two bands were observed in liver homogenate for
GST3 (25 and 26 kDa).
Experimental design and statistical analysis. Quantitative data related to
animal physiology, barrier function, and enzymatic processes are re-
ported as the mean  SEM. Data from RT-qPCR analysis are expressed as
the mean  SD. Multigroup comparisons were analyzed using one-way
ANOVA followed by a Tukey’s multiple-comparison test. Statistical
analyses involving two groups of data were performed using either a
one-tailed or two-tailed Student’s t test, as appropriate. Lateral and
fourth ventricle choroid plexuses were dissected and analyzed separately
in each animal, or in batches of animals. Analyses of differences between
these two tissues were therefore performed using a paired t test. For
clarity, the statistical tests used are specified in each figure. The number
of samples analyzed per group was chosen in reference to similar previ-
ously published experimental approaches conducted by our group on
choroid plexuses. These numbers are indicated on graphs or in figure
legends. All qualitative data presented have been reproduced at least
twice on different batches of materials.
Results
Enzymatic glutathione conjugation at the blood–CSF
interface efficiently protects the CSF and brain during
postnatal development
Substrates like CDNB or MCB are conjugated with GSH by the
whole subset of GST isoenzymes involved in xenobiotic detoxifi-
cation (Eklund et al., 2002; Hayes et al., 2005). Conjugation of
either compound therefore reflects the overall GST-dependent
detoxifying capacity of a given tissue. While CDNB conjugation
produces a metabolite that is readily detected and quantified by
HPLC, MCB presents the advantage in generating a fluorescent
conjugate that can be detected by both spectrofluorimetry and
cellular imaging techniques. We first used MCB to establish the
postnatal developmental profile of GST activity in tissue homog-
enates prepared from lateral and fourth ventricle choroid plex-
Table 1. Primers used for RT-qPCR
Target gene Forward primer sequence 5  3 Reverse primer sequence 5  3 Product size (bp) MgCl2
GSTM1 CCA CAT TTT TGA GCC CAA GT TGA GTG CCA GTG TAG CAA GG 179 3 mM
GSTM2 TTC GCC TGT TCC TGG AGT AT CCA TAG CCT GGT TCT CCA AA 267 3 mM
GSTM3 CAT CCC GGA GAA GAT GAA AA CAG GTC TTG GGA GAA AGC TG 233 3 mM
GSTM4 TAC AAG GGT GGC TAC TTG GG GCC TAG GCT GTA GAG GGC TT 191 3 mM
GSTM5 GGT TTG CAG GAG AAA AGC TG TGA TTG GCA TCT TGA AGC AG 186 3 mM
GSTM6 ACG GAA GCC TGA GTT CTT GA CCA CGT GGC CTG TTT TAA GT 280 3 mM
GSTA1 AGT TGG GAG CTG AGT GGA GA TTT GGT GGC GAT GTA GTT GA 297 3 mM
GSTA3 CAG CCA GAG GAA GCC ATT AG CCC AGC AAT TCC TCA TCA GT 228 3 mM
GSTA4 GTT CCT GCA GAC AAA ATC CC GCA TCC ATC CTT TTG CAA CT 195 4 mM
GSTP1 TGT ACT TCC CAG TTC GAG GG GGG TGA GGT CTC CAT CTT CA 168 3 mM
Arab (Escherichia coli) ATC CCC TGA TCG GTA AAG CA ACG CCT GAA AGG GGT GAT TA 126 4 mM
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uses, and from cerebral cortex (Fig. 1). Liver, which is the main
detoxifying organ in the body, was analyzed in parallel as a refer-
ence tissue. Glutathione S-transferase-specific activity increased
sharply in liver in P35 animals compared with P2 pups, indicating
the relative immaturity of this organ at birth in the rat. In con-
trast, GST activity was already high in both types of plexuses in
newborn animals and was higher than in the brain cortical tissue.
From 5 weeks on, the activity toward MCB measured in the cho-
roidal tissue from the fourth ventricle was twice that measured in
the choroidal tissue from the lateral ventricle, as also observed
when using CDNB as a substrate (Ghersi-Egea et al., 2006). The
activity in choroid plexuses from the fourth ventricle remained
significantly higher than in the cerebral cortex at all developmen-
tal stages.
To explore the GST-dependent conjugating capacity of live
choroidal epithelial cells and investigate the fate of the metabo-
lite, we exposed freshly isolated choroid plexuses to 10 	M MCB
and recorded fluorescence images in a plane cutting through both
the epithelium and the stroma (Fig. 2A–F). The choroidal epithe-
lium became rapidly and intensely fluorescent (Fig. 2C,E, arrow-
heads), indicating that MCB is readily conjugated to GSH within
epithelial cells. The fluorescence in the epithelial layer decreased
thereafter (Fig. 2D,F), likely as a result of the sharp drop in MCB
concentration that we measured in the incubation medium (data
not shown) and the concomitant cellular export of the fluores-
cent metabolite, which was observed in the underlying stroma at
4 min (Fig. 2F, arrows). This suggests that the conjugate is ex-
ported from the cells at least partially at the basolateral mem-
brane. To get more insight into the conjugation capacity of the
choroidal epithelium and to characterize the polarity of conju-
gate efflux from the choroidal cells, we used an in vitro cellular
model of the blood–CSF barrier (Fig. 2G), which closely repro-
duces the properties of the choroidal epithelium in vivo. In par-
ticular, cells in culture maintain the drug metabolism capacity of
the native tissue, including its high GST-specific activity (Stra-
zielle and Ghersi-Egea, 1999; Strazielle et al., 2003). Epithelial
cells were exposed to 5 	M MCB in the lower compartment of the
bichamber culture device. The basolateral to apical (blood to
CSF) diffusion of MCB across the epithelial monolayer was com-
pletely prevented for up to 30 min, presumably by intracellular
MCB conjugation, and remained low thereafter (Fig. 2H). Over
the 60 min period, the clearance of MCB did not exceed the
clearance of sucrose used as a paracellular marker (data not
shown). Adding CDNB as a competitor (data not shown) or
raising the MCB concentration from 5 to 50 	M (Fig. 2H) ne-
gated the barrier effect. To ascertain the metabolic nature of this
barrier mechanism, the appearance of the conjugate GS-MCB in
the basolateral and apical compartments and its intracellular
concentration were monitored by HPLC analysis after a 30 min
exposure to 5 	M MCB. The conjugate was indeed produced and
secreted from epithelial cells, and its efflux rate was 10 times
higher at the basolateral membrane compared with the CSF-
facing membrane (Fig. 2I). The conjugate was below detection
level in the cell monolayer. When choroidal epithelial cells were
preincubated with probenecid, an inhibitor of large specificity for
organic anion transporters, GS-MCB efflux was reduced at both
basolateral and apical membranes and its intracellular concentra-
tion increased (Fig. 2I). Collectively, this set of data confirms the
strong basolateral (blood-facing) polarity of efflux that we ob-
served in freshly isolated choroid plexuses, and demonstrates that
cellular export of the GSH conjugate is mediated by organic an-
ions transporters at both membranes.
We then assessed in vivo the efficacy of this enzymatic barrier
mechanism in preventing the diffusion of GST substrates from
blood to CSF during brain development. The blood–CSF barrier
permeability to CDNB was measured in rat pups displaying either
a normal or a low capacity to conjugate xenobiotics to GSH in the
choroid plexus. CDNB was chosen over MCB as it can be unam-
biguously detected and quantified in biological fluids including
CSF by HPLC. It is also more soluble than MCB and could be
used at the high concentration required to approach the maximal
GSH-dependent conjugation capacity of the blood–CSF barrier.
Functional knockdown of GSH conjugation in choroid plexuses
of developing animals was achieved by treating P2 rats with three
injections of BSO over a 36 h period. Buthionine sulfoximine is a
selective inhibitor of -glutamyl cysteine ligase, which catalyzes
Figure 1. Glutathione S-transferase-specific activity in liver and brain tissues in the rat during postnatal development. The specific activity of GST was measured using MCB as a substrate in liver
(A) and brain tissue (B) homogenates prepared from P2, P7, P35, and adult (Ad) animals. Data are the mean  SEM; n 
 4 – 8. ***p 	 0.01, statistically different from cerebral cortex activity at
matching developmental stage, one-way ANOVA followed by post hoc Tukey-Kramer test. §p 	 0.05 and §§§p 	 0.001, significantly different from the activity measured in choroid plexus of the
fourth ventricle, two-tailed paired Student’s t test. CP(VL) and CP(4V), CP of the lateral and fourth ventricle, respectively; Cx, cortex.
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the first and rate-limiting step in GSH
synthesis. Four hours after the last injec-
tion, the treatment led to an almost com-
plete (92%) depletion of GSH in both the
fourth and lateral ventricle choroid plex-
uses, while the depletion was only partial
(60%) in the brain parenchyma (Fig. 3A).
This mild BSO treatment did not induce
any overt toxicity, as it modified neither
the feeding behavior of P2 rats nor their
weight gain (Fig. 3B). It did not change the
GST intrinsic enzymatic activity in either
the brain parenchyma or the choroid
plexus (Fig. 3C). Finally, this treatment
did not alter the integrity of CNS barriers,
as shown by the similar CSF and brain Kin
values measured for sucrose in control
and treated animals (Fig. 3D).
Four hours following the last BSO in-
jection, animals were underwent intracar-
diac perfusion of CDNB followed by CSF
sampling. In control animals, CDNB was
not detected in the CSF when the com-
pound was perfused at concentrations up
to 200 	M, but was measured at a low level
when the perfusate concentration was
raised to 500 	M (Fig. 4). The depletion of
choroidal GSH resulted in a substantial
increase in CDNB influx in CSF at both
concentrations. When the xenobiotic was
perfused at 500 	M, its concentration in
CSF was 30-fold higher in depleted rats
than in control animals. The outflow per-
fusate collected from the cardiac atrium
did not show any significant difference in
CDNB concentration between control
and BSO-treated animals (Fig. 4, insert),
ruling out a possible peripheral effect of
the depleting agent on the xenobiotic dis-
tribution. The large difference in CDNB
levels in CSF observed between control
and choroidal GSH-depleted animals
demonstrates that the GSH-dependent
metabolic activity of the blood–CSF bar-
rier effectively contributes to protect the
brain environment from blood-borne
chemical substrates during development.
The ependyma participates in cerebral
glutathione-dependent detoxification
Exposure to toxic molecules for a pro-
longed period may ultimately overcome
this choroidal neuroprotective metabolic
mechanism. The ependymal cells lining
the ventricular system will become the
first targets. To address the possibility that
these cells could be a site of subsequent
protection, we evaluated their conjugat-
ing capacity by infusing MCB in the lateral
ventricles of P4 rats. A strong fluorescence
reflecting GS-MCB production was ob-
served at the ependymal interface in the
ipsilateral ventricle of animals killed
Figure 2. Enzymatic conjugation of MCB to glutathione in the blood–CSF barrier. A, Method: GST-mediated conjugation of the
substrate MCB with GSH produces a fluorescent metabolite that can be monitored over time. B–F, Ex vivo exposure of freshly
isolated choroid plexuses to MCB led to the rapid formation of the fluorescent GSH-conjugated metabolite within epithelial cells
(arrowhead in C and E). After 4 min, the fluorescence signal decreased in the choroidal epithelial cells (arrowheads in D and F ), and
seemingly concentrated in the underlying vessel containing stroma (arrows in E and F ). B is a negative control. B–D and E, F show,
respectively, low-magnification and high-magnification images of the choroidal tissue exposed to 10 	M (C–D) and 2.5 	M (E–F )
MCB. In F, the dashed line delimits the apical membrane of epithelial cells. Scale bar, 20 	m. G–H, Choroid plexus epithelial cells
cultured on a porous filter (G) form an enzymatic barrier preventing the basolateral to apical transfer of MCB. When MCB was added
to the basolateral compartment at a concentration of 5 	M, the appearance of the parent compound in the apical compartment
was fully impeded for 30 min and remained strongly limited thereafter (H, full line). When the cells were exposed to 50 	M MCB,
the enzymatic barrier effect lasted only 10 min, and the MCB clearance rate strongly increased thereafter (H, dashed line). I,
Excretion of the conjugate produced within the choroidal epithelium was highly polarized, 90% of the metabolite being found in
the basolateral medium. The conjugate was not detected intracellularly (black bars, cells exposed to 5 	M MCB for 30 min). When
cells were preincubated with 3 mM probenecid before MCB exposure, GS-MCB efflux was strongly reduced at both basolateral and
apical membranes, and the metabolite accumulated in the epithelial cells (gray bars). Data are the mean  SEM of four filters.
**p	0.01 and ***p	0.001, statistically different from GS-MCB amount in the absence of probenecid, one-tailed Student’s t test
for unequal variance. nd, Not detected.
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within a minute from the beginning of the infusion, indicating
that ependymal cells also have a high GSH conjugation capacity
(Fig. 5A). The contralateral ependyma, used as a negative control,
did not show any fluorescence above background level (Fig. 5B).
A similar GSH conjugation activity toward MCB was observed
downstream in the ventricular system, namely in the ependyma
of the third ventricle (Fig. 5C). Monochlorobimane conjugation
was further explored in ependyma-containing brain slices pre-
pared from developing animals (Fig. 5D–F). Six-day-old animals
were selected for these studies because at this developmental stage
the ependyma appears mostly as a single layer, thus allowing a
clear delineation between the ependymocytes and the adjacent
tissue, and a more precise quantification of the signal. Following
MCB addition to the slice incubation medium, a bright fluores-
cence reflecting the production of the GSH conjugate rapidly
appeared within the ependymal layer, as illustrated at the level of
the ventral part of the third ventricle (Fig. 5E). Production of the
GSH conjugate in the ependyma was higher than in the adjacent
brain parenchyma (Fig. 5E,G). The ependymal fluorescence in-
tensity decreased after a few minutes (Fig. 5F), presumably due to
the transporter-mediated efflux of the polar metabolite from
ependymocytes. Accordingly, the addition of 2.5 mM probenecid
in slice incubation medium prevented the decrease in fluores-
cence (Fig. 5G). Identical images were recorded for the ependyma
bordering the aquaduct (data not shown). Collectively, these data
show the ability of the ependyma to act as a second line of defense
toward electrophilic compounds that could have bypassed the
blood–CSF barrier and reached the CSF.
GSH conjugation at the blood–CSF and CSF– brain interfaces
results from the expression of several multispecific
isoenzymes
To probe into the diversity of molecules that could be detoxified
by the choroid plexus during development, we performed GST
activity competitive inhibition studies. The spectrophotometric
method using CDNB as the substrate was chosen over the fluori-
Figure 3. Characterization of the choroid plexus glutathione-depleted animal model. A, Levels of GSH in tissue from animals treated with BSO. Choroidal tissue is depleted from GSH by 90%,
while 40% of GSH is still present in brain tissue after BSO treatment. Data are calculated as micromoles per milligram of tissue and are expressed as the percentage of values measured in
DMSO-treated control animals, and the mean  SEM (n). *p 	 0.05, **p 	 0.01, ***p 	 0.001, different from control animals. $$p 	 0.01, different from Cx or Pons, two-tailed Student’s t test
for unequal variance. LVCP and 4VCP, choroid plexuses from the lateral and fourth ventricle, respectively; Cx, Cerebral cortex; Hyp, hypothalamus. B, Animal weight from the time of treatment
initiation (T0) to the time of killing, 4 h following the third injection (T28). Animals were treated by three injections of BSO or vehicle (control). A typical experiment is shown. Data are expressed as
the percentage of weight at T0, mean  SEM, n 
 6. No difference in weight gain was observed between the two groups of animals. C, Enzymatic GST activity toward CDNB in homogenates from
tissue sampled from control (black bars) and GSH-depleted (gray bars) animals. BSO treatment did not induce any significant change in GST-specific activity. Data are expressed as the mean  SEM,
n 
 3. D, Blood–CSF permeability constant (Kin csf) and apparent blood– cerebral cortex permeability constant (AppKin Cx) for [
14C]-sucrose in control (black bars) and BSO-treated (gray bars)
animals. No difference in permeability was observed between the two groups of animals, indicating that the integrity of the blood– brain and blood–CSF barriers is preserved following BSO
administration. Data are expressed as the mean  SEM, n 
 5.
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metric method with MCB to avoid interference of the competi-
tors with the fluorescent signal. Choroidal CDNB conjugation
was inhibited by several xenobiotics such as dietary additives,
pharmacological drugs, or products of oxidative stress, which are
all potentially toxic (Table 2). The inhibitory effect of these com-
pounds on GST activity was similar in choroid plexuses of the
lateral ventricle and fourth ventricle. Large differences were ob-
served among molecules in their effective concentration and in
the extent of inhibition. As detoxifying GST isoforms display
differential substrate specificities toward the competitors tested,
while CDNB is conjugated by all these isoenzymes, this suggests
that several isoforms are active in choroid plexuses. Extensive
multiple-concentration inhibition studies were not performed as
they requested an ethically unacceptable number of developing
animals to generate the required amount of choroidal tissue.
We then determined by RT-qPCR the GST isoenzyme expres-
sion profiles in lateral ventricle choroid plexus, fourth ventricle
choroid plexus, and cortical tissue at three developmental stages,
and compared it to the isoenzyme profile in liver. Two prepara-
tions each of brain cortical microvessels isolated from P9 and
adult rats were also analyzed (Fig. 6). We focused on isoforms
involved in detoxification processes, namely GST1 and the iso-
forms belonging to the 	 and  subfamilies. Differences in y-scale
values between graphs provide an approximation of the respec-
tive abundance of the various gene products in the samples.
Glutathione-S-transferase isoenzymes were expressed at higher
levels in the choroidal tissue forming the blood–CSF barrier than
in the microvessels forming the blood– brain barrier. Levels of
GST	 isoform mRNAs increased during development in liver,
while in choroid plexuses these isoforms were expressed at a
higher or similar level in P2 animals compared with adults.
GST	1 and GST	2 RNAs were the most abundant 	-isoform
transcripts in the choroid plexuses. At P2, the expression levels of
both genes in this tissue exceeded by far those measured in the
liver, especially in lateral ventricle choroid plexuses ( p 	 0.001).
The choroidal expression of GST	1 and GST	2 was also higher
than in the cerebral tissue (p 	 0.001 and p 	 0.05 for lateral and
fourth ventricle choroid plexuses, respectively). This was partic-
ularly striking for GST	2, whose messenger was barely detected in
the cerebral parenchyma.
These data were confirmed by Western blot analysis using an
antibody recognizing both 	1 and 	2 isoforms (Fig. 7A). The 	5
isoform displayed a differential level of expression between lateral
and fourth ventricle choroid plexuses (Fig. 6) that was not re-
flected at the protein level (Fig. 7B). Both choroidal tissues
showed high protein content by Western blot compared with the
cerebral cortex and the liver. High levels of GST1 expression
were detected in the liver, but not in the different brain tissues. In
contrast, similar expression levels were observed for GST3 in
choroid plexuses and liver (Fig. 6; p  0.05). These levels in-
creased with age and largely exceeded those measured in cortex.
This tissue-specific pattern was confirmed by Western blot (Fig.
7C). The expression of GST4 did not vary to a great extent
among tissues or with age. Finally, the choroid plexuses and the
cortex displayed higher amounts of GST1 transcripts than liver
at all developmental stages (p  0.05), the levels in brain tissues
being twofold higher in developing animals compared with
adults (Fig. 6). The high choroidal expression relative to the liver
was also observed by Western blot (Fig. 7D). In summary, the
high conjugation activity measured during postnatal develop-
ment in choroid plexuses compared with the cerebral cortex
(Fig. 1) should be mainly catalyzed by the isoforms GST	1,
GST	2, GST3, and possibly GST1.
To assess the GST isoenzyme profile in the CSF– brain inter-
face, ependymal cells were isolated by laser microdissection from
the lateral ventricle wall at three developmental stages (Fig. 8A),
and their mRNA was extracted and analyzed by RT-qPCR. The
data were compared with those obtained from laser-microdissected
adjacent neuropil (Fig. 8B). In the ependyma, all 	-isoforms were
expressed at P2 at levels as high or higher than those measured at
later stages (Fig. 8C). The most abundant mRNAs were found for
GST	1 and GST	5. Their expression level was 11 and 12 times
higher in the ependyma than in the adjacent neuropil. GST3 was
also expressed at higher levels in ependyma than in the adjacent
neuropil, its expression increasing with age in both tissues. GST1
expression was modest and similar between structures and devel-
opmental stages. Thus, the high conjugation capacity of the
ependyma, relative to the brain parenchyma that was observed at
P6, appears mainly related to the GST isoforms 	1, 	5, and pos-
sibly 3.
Discussion
This article describes a GSH-dependent metabolic pathway that
is especially active during early postnatal development, and by
which the blood–CSF barrier prevents harmful compounds from
circulating through the CSF– brain system. The GST activities
measured in tissue homogenates at different developmental
stages indicate that during the postnatal period the GSH conju-
gation capacity of the choroid plexuses is especially high com-
pared with that of the cerebral tissue. It is also higher than the
activity measured at the same age in the liver, which is the refer-
ence organ for detoxification processes (Gundert-Remy et al.,
2014). This finding was supported by RT-qPCR and Western blot
data showing the elevated expression of multiple GST isoforms in
Figure 4. In vivo efficacy of the glutathione-dependent metabolic activity of the blood–CSF
barrier toward CDNB. Levels of CDNB were measured in the CSF sampled from control animals
(black) and animals depleted in choroidal GSH (BSO treated, gray) in P3 rats perfused with 200
or 500 	M CDNB. Data are expressed as the mean  SEM, (n). **p 	 0.01, statistically different
from control animals, one-tailed Student’s t test for unequal variance. Insert shows no changes
in CDNB concentration measured in the outflow perfusate collected from the cardiac atrium
between control and BSO-treated animals (mean  SEM, no statistical difference).
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choroid plexus compared with cortex and liver during postnatal
development. Live imaging of the metabolite formation in iso-
lated choroid plexus illustrated the early functionality of the
GST-mediated detoxifying pathway. Using a functional GSH
conjugation knock-down strategy resulting in a selective and ex-
tensive GSH depletion in choroid plexuses, we showed that the
high conjugation capacity of this interface translates into an effi-
cient metabolic blood–CSF barrier, preventing the penetration
and accumulation of GST substrates into the CSF during early
postnatal development. Assuming that CDNB plasma concentra-
tion increased linearly from 0 to 500 	M over the 5 min perfusion
in P3 animals in the present study, the influx permeability con-
stant Kin csf for CDNB calculated as in the study by Ghersi-Egea
et al. (2015) would be 0.3  103/min in control pups. Sucrose,
used as a polar marker of the integrity of the blood–CSF barrier,
has Kin csf values of 2.9  10
3/min in P2 rats and 2.6  103/min
in P9 rats (Ghersi-Egea et al., 2015). The permeability of the
blood–CSF barrier to the lipophilic compound CDNB, even
when used at a high concentration, was therefore lower than that
of cell membrane-nonpermeating molecules in control animals.
Choroidal GSH depletion increased CDNB permeability 30
times, without affecting the barrier integrity. These findings dem-
onstrate the great efficacy with which the choroidal enzymatic
barrier pathway reduces the blood-to-CSF permeability of lipo-
philic molecules. The enzymatic mechanism is further coupled to
the polarized excretion of the metabolites at the basolateral mem-
brane of the epithelium for their subsequent elimination through
the choroidal blood stream. The small fraction of the detoxified
polar metabolite that is effluxed at the apical membrane could be
further eliminated from the brain by the CSF bulk flow. Gluta-
thione S-transferase activity in choroid plexuses in the develop-
ing human brain is as high or higher than the choroidal activity in
newborn rats, and is also several fold higher than in the human
neuropil (Ghersi-Egea et al., 2006). The potent enzymatic blood–
CSF barrier we demonstrated in rat should also be efficient in the
human neonate brain.
Figure 5. Conjugation to glutathione in the ependyma. A–C, Intracerebroventricular injection of MCB induced a rapid and strong fluorescence signal in the ependyma, reflecting GS-MCB
production in these cells. In the lateral ventricle close to the site of injection, the signal was seen in both the ependyma and choroid plexus (A). The contralateral ventricle was used as a negative
control (B). The ependyma of the third ventricle was also labeled within 1 min following MCB injection (C). D–F, Freshly prepared ependyma-containing brain slices also generated GSH conjugates
upon addition of MCB to the medium. D represents the initial image before MCB addition. The fluorescent metabolite GS-MCB was rapidly produced at a higher level in the ependyma than in the
adjacent brain tissue (E). The concentration of GS-MCB in ependyma decreased over time (F ). G, Relative quantification of fluorescence intensity recorded in the ependyma and adjacent brain tissue
in the presence or absence of 2.5 mM probenecid. Data are expressed as percentage values of the signal measured in ependyma in the same slice 0.7 min after MCB addition; data are the mean 
SEM (n 
 6). The box in E shows a typical area from which a fluorescent profile was obtained and analyzed (see Materials and Methods). *p 	 0.05 and ***p 	 0.001, statistically different, paired
t test for unequal variance. $p 	 0.05, statistically different, one-tailed t test for unequal variance. CP, choroid plexus; Ep, Ependymal layer; VL, lateral ventricle; 3V, third ventricle; PB, probenecid.
Scale bars: A–C, 100 	m; D–F, 50 	m.
Table 2. Inhibition of the choroidal glutathione S-transferase activity by
environmental chemicals and therapeutic drugs
Potential substrate
Potential
substrate
concentration
(	M)
Reference
substrate
concentration
CDNB (	M)
Origin of
choroid
plexus
Inhibition
(%)
Ethacrynic acid 5 200 4V 91.7  1.5
LV 81.2  4.9
Bromosulfophtalein 40 200 4V 72.0  3.5
LV 73.3  3.8
Menadione 80 200 4V 41.2  7.4
LV 50.0  19.5
MCB 200 200 4V 77.7  1.5
LV 82.7  2.1
Chlorambucil 200 200 4V 83.5  3.8
LV 84.6  2.7
Benzyl-isothiocyanate 500 200 4V 84.7  3.2
LV 79.5  6.7
Sulforaphane 200 50 4V 26.7  5.5
LV 19.5  6.2
Trans-4-phenyl- 500 50 4V 58.1  7.0
3-buten-2-one LV 53.5  6.9
Acrolein 500 50 4V 53.4  10.1
LV 48.4  10.3
Cisplatin 500 50 4V 41.5  9.3
LV 27.7  10.3
The potential substrates include diuretic, anticancer, or diagnostic drugs (ethacrynic acid, bromosulfophthalein,
chlorambucil, cisplatin); dietary supplements and flavoring agents (menadione, trans-4-phenyl-3-buten-2-one);
phytochemicals (benzyl-isothiocyanate, sulforaphane); or environmental pollutants (acrolein, also a product of lipid
peroxidation). The competition was tested using the multispecific GST substrate CDNB as a reference substrate in
both lateral ventricle and fourth ventricle choroid plexuses. Data, expressed as percentages of activity inhibition, are
mean values  SD (n 
 3– 4 from multiple CP pools). Owing to the limited choroidal material available per litter,
they were generated for only one efficient competing concentration. The reference substrate concentration was
typically 200 	M. When a low inhibition was observed, CDNB was tested at a lower concentration to increase the
inhibitory action of the compound. The average specific activities measured in lateral ventricle choroid plexus tissue
in the absence of inhibitors were 96  22 and 54  10 nmol/min/mg of proteins toward 200 and 50 	M CDNB,
respectively. The same activities measured in fourth ventricle choroid plexus tissue were 87  15 and 48  10
nmol/min/mg of proteins (Data are the mean  SD of three different batches).
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Figure 6. Developmental profiles of glutathione S-transferase transcript levels in choroid plexuses, cerebral cortex, cerebral microvessels, and liver in the rat. RT-qPCR was performed in tissues
sampled at three developmental stages. For each isoenzyme gene, the right panel shows data obtained for cerebral structures, and the left panel shows liver data. The results, expressed relative to
the bacterial AraB gene added as an external standard, are shown as the mean  SD, n 
 4, except for the microvessels, for which values represent the mean (Figure legend continues.)
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During the perinatal period, the brain tissue is still poorly
vascularized (Caley and Maxwell, 1970; Saunders et al., 2012),
and the choroid plexuses represent a major gate of entry into the
CNS. The CSF represents 20% of the cranial cavity volume in P2
rats (Ghersi-Egea et al., 2015). It is considered to play a pivotal
role in the delivery of multiple guidance molecules and growth
factors to brain structures for their development and maturation
(Redzic et al., 2005; Lehtinen et al., 2013). Several of these trophic
factors are secreted into the CSF by the choroid plexuses, which
grow and mature early during the embryonic period (Dziegielewska
et al., 2001; Johansson et al., 2013; Lehtinen et al., 2013). By means of
their potent enzymatic barrier activity, the plexuses will prevent
a similar intracerebral distribution of deleterious electrophilic
endobiotics/xenobiotics. They will thereby fulfill a crucial neuro-
protective function during development, at a time when the liver
is still immature in its xenobiotic metabolism activity (Coughtrie,
2015; Fig. 1).
The GSTs form a multigenic family whose members display
different, yet partially overlapping, substrate specificities. Conju-
gation of CDNB in choroid plexuses was partially or completely
inhibited in the presence of various chemicals. Published catalytic
efficiency or affinity data showed that some of these molecules are
preferred substrates for specific GST isozymes. For instance,
bromosulfophthalein and trans-4-phenyl-3-buten-2-one are
preferred substrates for rodent GST	 isoforms (Hayes and Pul-
ford, 1995; Sano et al., 2002). Cisplatin is a preferred substrate for
GST1 and ethacrynic acid for both GST1 and 4 (Hayes and
Pulford, 1995; Nagar et al., 2015). Both ethacrynic acid and its
GSH conjugate also inhibit various other rat GSTs, in particular
	-isoforms, with IC50 values 	5 	M (Ploemen et al., 1990). Data
4
(Figure legend continued.) of two preparations. Gene expression levels did not differ by 44%
between the two age-matched microvessel preparations or were both low (	0.3). The results
are expressed as arbitrary units and are all normalized to the expression level found for GST	1
in one sample of liver obtained from an adult animal and set arbitrarily at 100 (see Materials and
Methods; for details on calculations, see Kratzer et al., 2013). *p 	 0.05, **p 	 0.01, ***p 	
0.001, statistical significance of differences in expression levels between developmental stages,
analyzed by one-way ANOVA followed by a Tukey’s multiple-comparison test. $p 	 0.05 and
$$p 	 0.01, statistical significance of differences in expression levels between age-matched
choroid plexuses of the lateral and fourth ventricle, two-tailed paired Student’s t test. For clarity,
other relevant statistical significances, assessed by one-way ANOVA followed by a Tukey’s
multiple-comparison test are stated in the Results section. CP(LV) and CP(4V), choroid plexuses
from the lateral and fourth ventricles, respectively; Cx, Cerebral cortex; MV, cerebral
microvessels.
Figure 7. Western blot analysis of several GST isoforms in choroid plexus isolated from the lateral and fourth ventricles of the developing rat. Tissue was isolated from 2 P2 (A, C, D) and P9 (B)
animals. A, The GST	1/2 isoenzymes are expressed at a higher level in choroid plexuses than in the cerebral cortex and liver. B, Both types of choroid plexuses display similar levels of the GST	5
protein, which are higher than in the cerebral cortex and liver. C, The GST3 protein is abundant in both types of choroid plexuses relative to the cortical neuropil. D, The GST1 isoenzyme is highly
enriched in the choroid plexuses compared with the liver and is also more abundant than in the cerebral cortex. All analyses were repeated on two different sets of samples. CP(LV) and CP(4V), choroid
plexuses from the lateral and fourth ventricles, respectively; Cx, Cerebral cortex; Li, liver; MW, molecular weight markers.
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generated with human enzymes showed that acrolein is a pre-
ferred substrate for GST  while benzyl-isothiocyanate is metab-
olized by both 	1 and 1 isoforms (Berhane and Mannervik,
1990; Kolm et al., 1995). The pattern of inhibition produced by
this large spectrum of molecules toward the multispecific GST
substrate CDNB indicates that multiple isoenzymes of GSTs are
significantly active in the choroid plexuses during the early post-
natal period in rat. This was corroborated by the high levels of
expression in the developing choroid plexus of various isoen-
zymes belonging to different GST classes, namely GST	1, GST	2,
GST3, GST4, and GST1. This unusually large pattern of
isoenzymes is reminiscent of the adult liver GST load. For all
compounds tested, differences in the extent of GST inhibition
between lateral ad fourth ventricle choroid plexuses were minor,
indicating that the forebrain and hindbrain blood–CSF interfaces
display a similar broad spectrum of xenobiotic detoxification.
The competitive inhibition study also showed that choroid plex-
uses metabolize a large range of structurally unrelated chemicals,
including different drugs; cytotoxic, carcinogenic, or genotoxic
electrophilic compounds issued from oxidative insults; environ-
Figure 8. Glutathione S-transferase transcript levels in ependymal cells and adjacent neuropil during postnatal development. A, Top, An example of a tissue section before and after laser
microdissection of the ependyma. The lower sections show the ependyma microdissected from the tissue and a preparation of pooled microdissected ependyma. B, The two panels show the area
of adjacent neuropil analyzed and the microdissected tissue obtained. C, Transcript levels of selected GST isoenzymes at three developmental stages. The results, expressed relative to the bacterial
AraB gene added as an external standard, are shown as the mean  SD, n 
 3. The results are expressed as arbitrary units and are all normalized to the expression level found for GST	1 in one
sample of ependyma obtained from P2 animals, and set arbitrarily at 100. GST1, GST4, and GST	6 were not detected in microdissected samples. *p 	 0.05 and **p 	 0.01, statistical
significance of the difference in expression levels between the ependyma and the adjacent neuropil, one-tailed paired Student’s t test. §p 	 0.05 and §§§p 	 0.001, statistical significance of the
differences in expression levels in P9 and adult animals compared with P2 animals in a given tissue, one-way ANOVA followed by a Tukey’s multiple-comparison test. Ep, Ependyma; P2ep and P2n,
ependyma and adjacent neuropil from P2 rat; P9ep and P9n, ependyma and adjacent neuropil from P9 rat; ADep and ADn, ependyma and adjacent neuropil from adult rat.
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mental pollutants; or food additives (Table 2 legend). The blood–
CSF enzymatic barrier should therefore be essential to prevent
chemically induced abnormal neural development and reduce
the risks of periventricular and meningeal tumors.
Intracerebroventricular injections of MCB in developing ani-
mals revealed that, like the choroidal epithelium, the ependyma
displays a high conjugation capacity. Ex vivo conjugation exper-
iments performed on brain slices showed that GST-mediated me-
tabolism in the ependyma is markedly more active than in the
surrounding neuropil. This indicates that the ependyma could
act as a second line of defense for neural cells against electrophilic
molecules that would reach the CSF. According to GST mRNA
expression analysis, this protection remains active throughout
development up to the adult stage. Neural stem cell niches are
present in several discrete regions of the ventricular system, the
subventricular zone in the lateral ventricle (Chaker et al., 2016),
as well as subependymal regions of the third and fourth ventricles
(Lin et al., 2015). They contribute to physiological neurogenesis
and gliogenesis during brain development, and the lateral sub-
ventricular zone remains active later on in the healthy adult
brain. All these niches also participate in adult brain repair fol-
lowing injuries such as stroke. The detoxifying functions of the
ependyma may be essential to protect these regions throughout
life. Astrocytes fulfill neuroprotective functions as well, especially
against products of oxidative stress (Baxter and Hardingham,
2016). Because astrocyte growth and maturation occur at a late
postnatal stage, it is conceivable that during the perinatal period
ependymal GSTs play a major role in conjunction with choroidal
enzymes in the detoxification of potentially neurotoxic lipid per-
oxidation products released by neural cells (Lovell et al., 2000;
Hubatsch et al., 2002).
The profile of GST isoenzymes expressed in the ependyma
differs from that in the choroid plexuses. Histologically, the cho-
roidal epithelium and the ependyma share a neuroectodermal
origin. Yet, the marked differential expression of GST	5 and
GST	2 between these epithelial cell layers implies that they
should be considered as independent interfaces with respect to
their metabolic properties. The exact functional significance of
this difference calls for additional investigations.
To be fully efficient, GSTs need to work in concert with cellu-
lar efflux systems that can export the metabolites out of the pro-
ducing cells. In some instances, the efflux system can govern the
cell sensitivity to toxicants (Paumi et al., 2001). We showed that
intracellular GSH conjugates are exported by a probenecid-
sensitive organic anion transporter at both the ependyma and the
choroidal epithelium. The organic anion transporter Slc21a5 and
the export pumps Abcc1 and Abcc4, which transport GSH con-
jugates, are present at the basolateral membrane of the choroidal
epithelium (for review, see Ghersi-Egea et al., 2006). They likely
participate in the GSH-dependent detoxification pathway in cho-
roid plexus. The identity of the transporters involved in GSH
conjugate efflux in the ependyma is more elusive, and the trans-
porter-mediated ependymal efflux process discovered in this
work opens a new field of investigation on transport mechanisms
in the CSF– brain interface. Of note, the cystine/glutamate anti-
porter expressed in both the choroid plexus and the ependyma
(Sato et al., 2002; Lee et al., 2012) should favor de novo GSH
synthesis within these interfaces to replenish the intracellular
pool of this essential cofactor.
In conclusion, the GSH-dependent metabolic detoxification
capacity of the choroid plexuses and ependyma during the post-
natal period identifies these structures as key actors in the protec-
tion of the developing brain, at a time when the astrocytic
network is still immature and liver xenobiotic metabolism is lim-
ited. This reveals a new facet of the means by which the brain can
protect itself at a period of high vulnerability. The choroid plex-
us–CSF pathway is also highly significant for drug delivery into
the CNS during the perinatal period (Strazielle and Ghersi-Egea,
2016). Taking into account the metabolic process highlighted in
this work will be useful in understanding the mechanisms setting
the cerebral bioavailability of therapeutic agents at that develop-
mental stage, and to optimize neonatal and pediatric pharmaco-
logical treatments.
Note Added in Proof: The names of the authors were acciden-
tally incorrectly listed backwards in the Early Release version
published March 5, 2018. The author names have now been
corrected.
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ABSTRACT Drug bioavailability to the developing brain is
a major concern in the treatment of neonates and infants as
well as pregnant and breast-feeding women. Central adverse
drug reactions can have dramatic consequences for brain de-
velopment, leading to major neurological impairment.
Factors setting the cerebral bioavailability of drugs include
protein-unbound drug concentration in plasma, local cerebral
blood flow, permeability across blood-brain interfaces, bind-
ing to neural cells, volume of cerebral fluid compartments,
and cerebrospinal fluid secretion rate. Most of these factors
change during development, which will affect cerebral drug
concentrations. Regarding the impact of blood-brain inter-
faces, the blood-brain barrier located at the cerebral endothe-
lium and the blood-cerebrospinal fluid barrier located at the
choroid plexus epithelium both display a tight phenotype ear-
ly on in embryos. However, the developmental regulation of
some multispecific efflux transporters that also limit the entry
of numerous drugs into the brain through barrier cells is ex-
pected to favor drug penetration in the neonatal brain.
Finally, drug cerebral bioavailability is likely to be affected
following perinatal injuries that alter blood-brain interface
properties. A thorough investigation of these mechanisms is
mandatory for a better risk assessment of drug treatments in
pregnant or breast-feeding women, and in neonate and pedi-
atric patients.
KEY WORDS blood-brain barrier . cerebrospinal fluid .
choroid plexus . development . efflux transporters
ABBREVIATIONS
ADR Adverse drug reaction
BBB Blood-brain barrier
BCSFB Blood-CSF barrier
CNS Central nervous system
CSF Cerebrospinal fluid
INTRODUCTION
Drug bioavailability to the central nervous system (CNS) is a
major concern in neonatal and pediatric treatments. Both the
perinatal period lasting from the 28th week of gestation to one
month after birth and the postnatal period covering the first
few years of life in human are critical for neural cell matura-
tion and neuronal network formation. Overexposure to phar-
macologically active molecules or toxic xenobiotics, at these
periods of life can impair neural cell division, migration, dif-
ferentiation, and synaptogenesis. Consequences can be dra-
matic and include life-long neurological impairments. Hence,
dosage of drugs used to treat CNS diseases in newborn and
children needs careful adjustments. Using drugs to treat non-
CNS diseases in this population is also challenging, because of
the risk of potential central side effects.
Far too little accurate information is currently available on
drug efficacy, safety, pharmacokinetic, and pharmacodynam-
ic in the neonatal and pediatric population. The range of
approved therapeutic molecules available to treat CNS or
non-CNS diseases in neonates and children is very limited.
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Most of the drugs available on the market are not recom-
mended for the neonatal and pediatric population, although
such decisions have not been supported by scientific studies.
Limitation of drug approval also bears on placental permissive
drugs prescribed to pregnant women. Clinicians have a very
succinct number of approved drugs to treat mother illnesses,
or to prevent or treat the consequences of perinatal injuries
such as hypoxia, inflammation or infection in babies.
Therefore, prescription of unlicensed or off-label medicines
for those populations is very common, reaching 45 to 60% of
prescribed drugs in the pediatric population in Europe, and
more than 90% in the premature neonate subpopulation (1).
Not surprisingly, several studies have shown that in children,
the risk of developing adverse drug reactions (ADRs) is higher
for off-label and unlicensed medicines than for authorized
medicines (2–4). Like in adult, the risk of ADRs in children
is clearly dependent on the type of medicine used (e.g. anti-
cancer drugs have a high potential for ADRs) and on the
number of drugs administered. Large associations induce ad-
ditive risks and drug-drug interactions. This can explain why
ADRs occur in 10% of hospitalized children, which are often
polymedicated (2). According to prospective and retrospective
studies, ADRs in the pediatric population are frequently at-
tributed to anti-infectious, anti-epileptic, and non-steroidal
anti-inflammatory drugs (2,5,6). Drugs used to treat attention
deficit hyperactivity disorders, prescribed especially by physi-
cians from North America, are also involved in ADRs in the
pediatric population (5). The most frequently reported ADRs
in children are skin disorders, CNS disorders, and fever, with
CNS disorders amounting to 11–25% of ADRs (2,5,6).
Different types of drugs are suspected of inducing neurotoxic
ADRs. Retrospective studies suggested that exposition to an-
esthetics and sedatives during the first years of life amplifies the
rate of behavioral, learning, or developmental disabilities dur-
ing childhood. Anesthetic exposition concerns 3.5 to 4.5 mil-
lions of children under 36 months of age every year in the US
(7). Other therapeutic drugs, which can be taken by pregnant
women or breastfeeding mothers, can induce neurotoxic
ADRs. These include antiepileptic drugs, antidepressants
and corticosteroids (5,8). Even excipients can induce neu-
rotoxic effects. As an example, some surfactants can in-
hibit the protective efflux transport capacity of the blood-
brain barrier (BBB) (9).
To remedy this worrisome situation, governments encour-
age drug companies to provide new pediatric information by
extrapolating data on efficacy from adult to children if possi-
ble, or by conducting specific pediatric studies when necessary
(10,11). In 2002, the US Food and Drug Administration
(FDA) published the Best Pharmaceuticals for Children Act
(BPCA), which incites drug companies to conduct FDA-
requested pediatric studies. In 2003, this act was reinforced
by the Pediatric Research Equity Act, which permits FDA to
require pediatric studies under certain circumstances. Few
years later, the EuropeanMedicines Agency (EMA) organized
the Pediatric Regulation, which aims at facilitating the devel-
opment and availability of medicines for the pediatric popu-
lation. In particular, the EMA has conducted an important
survey among health professionals to precisely define pediatric
drug requirements (12). Analyzing this survey indicated that
for most drugs, dose information, efficacy, safety, and phar-
macokinetic studies in the pediatric population are lacking.
Cerebral drug bioavailability, pharmacology and toxicity are
especially poorly documented (13). The penetration of drugs
into the developing CNS is set by multiples parameters, some
relevant to general pharmacokinetic principles, other specific
to the anatomical organization and functions of blood-brain
interfaces, which change throughout brain development. Our
current partial knowledge of these developmental specificities
is reviewed in the next sections.
PHARMACOKINETIC FACTORS AFFECTING
CEREBRAL DRUG DELIVERY
IN THE DEVELOPING BRAIN
Plasma Drug Concentration
Plasma drug concentration over time is the first factor
influencing the cerebral availability of a drug. The factors that
influence drug pharmacokinetic in plasma during infancy and
adulthood are different (5). For instance, gut flora changes
during development, as well as gastric pH, which decreases
from neutral to acidic. Transdermal and pulmonary absorp-
tions are more efficient in young than in adult patients.
Overall blood flow is reduced in younger individuals. The
body water-to-body fat ratio is higher in children and this
increases the distribution volume of hydrophilic drugs. The
hepatic drug metabolism machinery differs between infants
and adults. For instance, the expression of the important drug
metabolizing cytochrome P-450 CYP3A4 is low at birth, and
increases sharply during the first 3 months of life. In contrast,
cytochrome P-450 CYP3A7 expression peaks shortly after
birth and disappears in adulthood in most individuals.
Finally, renal tubular secretion and glomerular filtration are
reduced in neonates, thus affecting drug elimination. (5). All
these deve lopmenta l d i f f e rences in absorpt ion ,
biodistribution, metabolism and clearance account for differ-
ences in plasma concentration profiles between adult and
newborn individuals, as illustrated for morphine in pig (14).
These age-related variations greatly impede a safe extrapola-
tion of drug plasma pharmacokinetic data from adults to
younger populations in human.
In adult, the blood-brain interfaces are not permissive to
proteins unless receptor-mediated transcytotic mechanisms
exist. As a result, the unbound drug concentration in plasma
is the driving force for drug penetration into the adult brain.
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This unbound drug concentration depends on the extent of
drug binding to different plasma proteins, whose respective
concentrations change throughout development. For instance,
fetuin concentration in plasma is higher in preterm babies
than in end-of-term babies (15). Total protein concentration
in plasma increases from 5.9 ± 0.4 to 7.2 ± 0.6 g/100 mL
between birth and adulthood, and albumin concentration
parallels this increase (16). These changes will affect the un-
bound drug fraction in plasma, hence their extent of brain
penetration. It is noteworthy that, especially during prenatal
development, drug-protein complexes may nevertheless reach
the cerebrospinal fluid (CSF) and the brain through the cho-
roid plexuses (see below). Finally, newborns and preterm in-
fants present higher levels of bilirubin bound to albumin than
the adult. In this young population, highly protein-bound
drugs can displace bilirubin from albumin to a greater extent
and cause a neurotoxic syndrome (17,18).
Factors Related to Specific Features of Brain Physiology
The overall cerebral drug concentration is also dependent on
factors pertaining to the physiology and anatomical organiza-
tion of the developing brain. The brain develops within the
cranial cavity in a liquid environment provided by the CSF
circulation. Blood-to-brain drug transfer can take place either
across the BBB located at the endothelium of the microvascu-
lature, or across the epithelium of the choroid plexuses that
forms the barrier between blood and the ventricular CSF (19)
(Fig. 1). The arachnoid membrane, which is part of the me-
ninges, forms a second barrier between blood and CSF, but is
a less significant gateway for drug entry into the brain, as it is
situated downstream in the CSF circulatory system. Because
of this complex blood-brain interface organization, brain-
specific factors influencing the distribution of drugs into this
organ are multiple, and their influence differs between the
developing and mature brain. A large part of our knowledge
about factors that set blood-brain exchanges during develop-
ment comes from experimental data gathered in particular in
rodents. Because birth occurs at an earlier stage of develop-
ment in rat and mouse as compared to human (20), some
aspects of the neonatal period in these animal species reflect
the situation of a late stage of gestation in human. This com-
plicates the extrapolation of experimental data on blood-brain
exchanges to human, but several main factors differently
influencing drug delivery to the developing and adult brains
can nonetheless be identified.
Brain Hemodynamics
The extent of penetration of highly CNS permissive drugs, i.e.
drugs completely extracted from the blood during the first
pass through the brain, is dependent on the local cerebral
blood flow (21,22). Experimental data show that this flow is
lower and more homogeneous among brain structures in the
developing than the adult brain (23). The local parenchymal
capillary density and the development of choroid plexus villi
set the surface area available for exchange across blood-brain
interfaces. In adult, the capillary density is very high, with
differences between brain structures. The white matter is less
vascularized than the grey matter (24). The choroid plexuses
also develop a significant surface area of exchange between
blood and CSF, owing to their anatomical organization in
numerous villi and to the peculiar morphology of their
epithelium presenting basal membrane infoldings and an
extensive network of microvilli at the apical membrane (25)
(Fig. 1). The density of the microvasculature increases during
pre- and postnatal development. The combined effects of a
decrease in neural cell density and an increase in the vascular
network in the rat cortex during the first three weeks of life
lead to a vessel-to-neural cells ratio that increases 23 times
between birth and 21 days of age (26). In contrast, the choroid
plexuses develop early in the fetal brain in mammals (27), and
already represent a large surface of blood-CSF exchange at
the perinatal period. In addition, choroid plexuses display the
highest cerebral blood flow of all cerebral structures, and the
choroid plexus-to-cortex local blood flow ratio is even higher
in the developing (ratio of 8) than adult (ratio of 4–6) brain
(28). Although choroid plexuses are still growing postnatally to
follow overall brain growth, the relative importance of the
choroidal blood-CSF barrier (BCSFB) versus the BBB as a gate
of entry into the CNS is higher during postnatal development
than in adult.
Permeability across Blood-Brain Interfaces
The permeability across blood-brain interfaces can vary be-
tween developmental stages. This is a determinant factor,
which depends on the efficiency of tight junctions, trans-
porters, and vesicular processes at brain barriers. This will
be examined in more details in the next section.
Drug Binding to - and Uptake by Neural Cells
Binding and uptake processes can occur in neurons, astro-
cytes, oligodendrocytes and myelin sheets. They explain the
apparent overall cerebral accumulation of certain drugs, but
because these processes decrease the free drug concentration
in the extracellular space, they diminish the efficacy of mole-
cules acting on plasma membrane receptors (29). While the
time of birth does not correspond to the exact same stage of
development among species (20), the sequence and relative
rate of progress of neural events that conduce to brain devel-
opment and maturation is very similar (20). Myelination oc-
curs gradually during pre- and postnatal development, and
astrocyte maturation happens mostly during the postnatal pe-
riod both in mouse and in human (20,30). The influence of
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such developmental changes on drug binding to neural cell
membranes is expected to be significant both in human and in
animal models used for drug pharmacokinetic studies, but this
has not been documented. Evaluating changes in unbound
drug concentration in the brain extracellular space during
development is further complicated by the presence of higher
amounts of plasma proteins in brain fluids of developing indi-
viduals compared to adults.
Dynamics of Interstitial Fluid and CSF Flows
The overall cerebral biodisposition of drugs is greatly influenced
by the three following factors: drug diffusion through the extra-
cellular space, drug circulation along perivascular spaces, and
the sink action of CSF. All three factors are evolving with age.
First, the extracellular space volume changes during postnatal
development. In rat, it represents about 40%of the parenchyma
volume in 2- to 3-day-old animals, and decreases thereafter to
reach the adult value of around 20% (26,31). Consequently,
drug diffusion rates within the brain parenchymal extracellular
space are likely to differ between developing and adult brain
(32). Second, drug circulation along perivascular spaces in both
directions (subarachnoid spaces to brain and vice versa) also
depends on the progressive establishment of the adult brain
vascular network. Third, the characteristics of the CSF circula-
tion differ greatly between developing and adult brain. TheCSF
is secreted mainly by the choroid plexuses. It flows through the
ventricles of the brain, then into the subarachnoid and cisternal
spaces, before being resorbed in the venous system through the
arachnoid granulations or in the lymphatics along cranial nerves
and olfactory bulbs (33,34). The ratio of CSF to brain tissue
volume is much higher in the developing brain than in the adult.
In rat, the volume of CSF relative to the cranial cavity is 3 times
higher two days before birth than nine days after birth (35) (Fig.
2). In addition, the rate of CSF secretion by the choroid plexuses
is lower in embryos and neonates than in adults (36,37, and
reviewed in 38). As a correlate, CSF flow rate is low in the
developing brain as compared to the adult brain (39), which
should favor drug accumulation into the CSF, even if the overall
CSF turnover (secretion rate as a percentage of CSF volume)
does not change much during development (40). Thus, CSF
could act as a large reservoir for drugs that crossed the
BCSFB, and the choroid plexus-CSF system is likely to
play a significant role in controlling drug concentration
into the parenchyma during the perinatal and postnatal
periods. As an example, morphine reaches higher concen-
tration levels in CSF in neonatal pigs as compared to
older animals, and the drug turnover in CSF is lower (14).
SPECIFICITIES OF BLOOD-BRAIN INTERFACE
PERMEABILITY TO DRUGS
DURING THE PERINATAL AND POSTNATAL
PERIODS
Mechanisms Regulating Blood-Brain Interface
Permeability to Drugs
The ability of pharmacological compounds to cross blood-
brain interfaces is a major factor setting their cerebral
Fig. 1 Schematic representation of the two major blood-brain interfaces. The left panel illustrates the flow of cerebrospinal fluid (blue) and the localization of the
choroid plexuses (red) in the human brain. The right panel is a cartoon representing the different tissues of the doted rectangle. The structural features of the
blood-brain barrier (BBB) and blood-CSF barrier (BCSFB) are illustrated. The endothelial cells of the microvessels, sealed with tight junctions (red circle), form the
BBB. They are in close proximity to pericytes (orange cell). Astrocytic endfeet (dotted grey cell membranes) unsheathe the microvessels. These astrocytic
processes appear only gradually during the peri- and postnatal stage of development. The epithelial cells of the choroid plexuses, also sealed by tight junctions,
form the BCSFB. Basolateral infoldings and apical microvilli extend the surface area available for regulated exchanges between the blood and CSF. The choroidal
capillaries do not display a BBB phenotype as they are fenestrated (purple circle). Modified from (72).
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bioavailability. In adult, as tight junctions seal both the endo-
thelial cells that form the BBB and the choroidal epithelial
cells that form the BCSFB, drug access to the brain is through
the transcellular pathway. Non-specific transcytosis does not
occur at the BBB. Drug entry into the brain occurs only for the
free fraction of the compound, through diffusion across cell
membrane, and is set by the lipophilicity and size of the drug.
Overton’s rule predicts blood-brain permeability to be rough-
ly proportional to the octanol/water partition coefficient of
the drug divided by the square root of its molecular weight
(21). Thus, highly polar compounds, especially large ones,
have a very limited access to the brain, unless they are sub-
strates for influx transporters. The latter systems are highly
specific for natural endogenous nutrients and micronutrients,
and seldom accept structurally modified substrates. They are
solute carrier (SLC) members, and contribute to the cerebral
delivery of only a few drugs (41,42 and reviewed in 43).
Examples include Slc16a1/Mct1 for valproic acid, Slc7a5/
LAT-1 for antiepileptic drugs such as gabapentin, and
Slc22a5/octn2 for cholinesterase inhibitors. These three
transporters locate on both membrane domains of the barrier
cells. By contrast, an array of multispecific efflux transporters
prevent or reduce the blood-to-brain and blood-to-CSF pen-
etration of a large range of lipophilic xenobiotics, including
immunosuppressor, antiretroviral, antibiotic, antitumoral, an-
tiepileptic, antidepressant, anti-inflammatory, antidiabetic,
and psychotropic agents (for bibliographic references, see
19). These transporters belong to the ATP Binding Cassette
(ABC) transporter families ABCC, ABCB, ABCG, and to the
SLC21/SLCO (organic anion transport polypetide) and
SLC22, SLC15, SLC29, and SLC47 subfamilies. These var-
ious transport proteins can also increase the elimination of
their drug substrates from the brain/CSF spaces (reviewed
in 19). Of note, a number of these therapeutic agents are
prescribed to pregnant women and may pass the placental
barrier (44). The main drug efflux transporters include
ABCB1 (p-glycoprotein), ABCG2 (breast cancer resistant pro-
tein), ABCC1 and 4 (multidrug resistance associated protein),
SLC22A8 (organic anion transporter 3), and SLCOs. At the
choroid plexus, an additional enzymatic barrier exists, that
metabolizes selected xenobiotics (45). Recent drug develop-
ment has introduced biotherapeutic macromolecules such as
antibodies. The brain bioavailability of immunoglobulins,
which from their size and polar nature are not prone to diffuse
across cellular membranes, is further limited by an efflux
mechanism located at both the BBB and BCSFB, likely in-
volving the FcRn receptor (19,46).
Transport Properties of Blood-Brain Interfaces
during the Perinatal and Postnatal Period
For decades, blood-brain interfaces of the developing brain
have been considered immature and Bleaky^. This immaturity
has been revisited, and it is now acknowledged that tight junc-
tions form precociously. It occurs both in the nascent cerebral
microvessels under the influence of the Wnt/β-catenin path-
way and of recruited pericytes, and in the choroidal epitheli-
um by a yet unknown mechanism (reviewed in 19). In human,
claudin 5, a landmark of BBB tight junctions, already seals
endothelial cells of brain vessels at 5–7 weeks post conception
(47). Similarly, claudin 5, ZO-1, and occludin form tight junc-
tions in cerebral endothelial cells in 12-day-old rat embryos
(30). Claudin 1, a landmark of BCSFB tight junctions, is pres-
ent at cell-cell contact between choroidal epithelial cells as
early as week 8 of gestation in human, and probably sooner
(48). These structural features efficiently seal the paracellular
pathway in both barriers, as demonstrated experimentally in
rat and opossum fetuses (49,50). Non-specific vesicular trans-
port across cerebral endothelial cells decreases rapidly during
fetal development, under the influence of pericytes (30,51).
Therefore, lipophilicity and size are key factors setting drug
diffusion through blood-brain interfaces in younger
Fig. 2 Cutting-plane photographs
of a whole-head mounted
specimen illustrating the importance
of CSF spaces in a 19-day-old rat
fetus. The blue lines delineate fluid
spaces (ventricles, subarachnoid
spaces, cisterns) and the cranial
cavity. Aq: aquaduct; Cb:
cerebellum; Cx: cerebral cortex; IC:
inferior colliculus; Med: medulla;
MG: Medial geniculate complex, P:
pons. Experimental protocol as
described in (35).
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individuals as in adult. As an example, in pig, a precocial
species whose brain developmental pattern closely mimics
that of primates (52), the transfer constant for mannitol
across the BBB in newborn was found similar to that
measured in adult (53).
There are however substantial differences in the expression
of drug influx and efflux transporters at the BBB and BCSFB
between the developing and adult brain. Developmental pro-
files of expression have not been thoroughly investigated for
all transporters. Among the few influx transporters mediating
drug entry into the brain (see above), MCT1 is expressed at a
higher level at the BBB in neonatal rat than in adult (54).
Owing to their more potent impact on drug delivery to the
brain, efflux transporters deserve more attention. The main
findings collected from the literature have been analyzed in
details in (55), and are summarized in Fig. 3. Three main
conclusions provided by these data are as follows.
First, the developmental pattern of expression of efflux
transporter genes is more stable in the choroid plexuses than
in the BBB. In the latter barrier, several efflux carriers are
expressed at substantially lower levels during development
compared to adulthood. In particular, although ABCB1 and
ABCC4 expression increases in cerebral capillaries during
preterm development, a period during which the placental
barrier efficiency decreases, it remains low around birth as
compared to the adult (reviewed in 55). This suggests that
the developing brain will be more sensitive to drugs that are
substrates for these efflux carriers. A quantitative analysis of
ABCB1 protein level in capillaries isolated from 9-day-old and
adult rats revealed a 5-fold difference between the two stages
(56). Assuming the conservation across species of the sequence
and progress of neural events setting brain development and
maturation (20) can be extended to those of blood-brain bar-
rier functions, these rodent data predict that infants would
have a lower BBB-associated ABCB1 protein level than the
adult human. This prediction is in line with immunohisto-
chemical and PET data collected in human and non-human
primates (reviewed in 55). The time of ABCB1 induction
and the lack of pericyte influence on this process suggest that
the upregulation of this transporter during development re-
sults from increasing astrocyte endfeet differentiation and in-
fluence on the BBB (30,57).
Second, several efflux transporters are expressed at
higher levels during development than in adulthood.
This occurs mainly in choroid plexus. Thus, like for influx
carriers (58), the developmental regulation of efflux trans-
porters seems to relate to stage-specific developmental
needs rather than reflect an overall immaturity of the
barriers, at least at the BCSFB site.
Third, species differences in transporter expression exist
and need to be taken into account when evaluating drug
transport to the developing brain. In the human BBB,
ABCG2 seems to be expressed at higher levels than ABCB1,
while the opposite is true in the mouse (59). Furthermore,
while ABCB1 expression level increases largely between neo-
nates and adults, ABCG2 expression remains steady through-
out development in the cerebral endothelium of all species.
These two transporters have partially overlapping substrate
specificities. Thus, variations in the BBB permeability to drugs
that are substrates of both ABC proteins between developing
and adult individuals will depend on the respective affinity of
these drugs for the two transporters, and may be less
Fig. 3 Drug efflux transporters at the blood–brain (left) and blood–cerebrospinal fluid (right) barriers in adult and during development. Both primary ATP-
dependent transporters (Abc) and other solute carriers (Slc) identified at the interfaces are shown. The major transporters are underlined. Some transporters
whose cell membrane location has not been formally established are named in italic. The expression or function of the transporters between parentheses is
debated. Transporters whose expression decreases from the perinatal to the adult stage are noted in blue. Transporters whose expression is stable during
development are noted in green. Transporters whose expression increases from the perinatal to the adult stage are noted in orange. Transporters whose
developmental profile is unknown appear in grey. Based on a detailed analysis of the literature described in (55).
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important in human than in rodents. Finally, the drug metab-
olism capacity of the choroid plexus tissue has not been exten-
sively investigated in the developing brain in human. Partial
findings, mainly obtained in rodents, suggest that these mech-
anisms are functional in choroid plexuses during the perinatal
period (60).
The downregulation of non-specific intracellular vesicular
transport through cerebral endothelial cells and the molecular
organization of efficient interendothelial tight junctions occur
rapidly after formation of neovessels in embryos, as a result of
pericyte-mediated signaling (51). This prevents albumin to
enter the brain through the BBB (61). Yet plasma proteins
are found in the brain, especially in the CSF, explaining why
the barriers were previously considered as immature and leaky
during development. The level of plasma proteins in the fetal
and neonatal CNS results from the low turnover of CSF at
these stages, and from the presence of specific protein-
transporting cells in the choroidal epithelium (reviewed in
19). It is conceivable that albumin-bound drugs can enter
the CSF and brain through these transporting cells. The sig-
nificance of this pathway for the entry of some drugs into the
CNS remains to be evaluated.
Finally, new generation drugs are appearing in the clinic,
or are currently under development. These include large mo-
lecular weight proteins such as antibodies, nanoparticle car-
riers developed for gene or enzyme therapies, engineered
cells, viral capsids. Some of these new generation drugs are
developed to treat brain illnesses, and mechanisms of protein
or particle translocation into the brain are explored. The most
promising approach appears to be through receptor-mediated
transcytosis, targeting BBB and BCSFB enriched receptors
such as members of the LRP family (55,62). These receptors
are important for normal brain function, and may display
developmental specificities to adjust the need of the maturing
brain. Hence, a thorough investigation of the expression and
function of these receptors throughout development is
needed.
INFLUENCE OF BLOOD-BRAIN INTERFACE
ALTERATIONS ON DRUG DELIVERY
TO THE DEVELOPING BRAIN
Several pathological events such as inflammation, hypoxia,
hyperbilirubinemia, or exposure to environmental toxicants
during the perinatal period can induce neurological adverse
effects. An alteration of the integrity of blood-brain interfaces
can occur during perinatal injuries, as blood-brain interfaces
display structure- and stage-specific sensitivity to different
stresses. First, some parts of the developing brain present a
physiologically more fragile BBB. For instance, the germinal
matrix is particularly prone to brain hemorrhage during peri-
natal development because this highly vascularized structure is
characterized by capillaries presenting a large diameter, a thin
basement membrane, and few pericytes (63). Second, inflam-
mation and infections produce complement proteins, pro-
inflammatory cytokines, and endotoxins that can affect the
BBB during development, in particular by modifying the ex-
pression and subcellular localization of tight junction proteins.
A specific susceptibility of the BBB following exposure to en-
dotoxin around birth has been documented. It results in pro-
tein extravasation into the white matter (64). Placental or ma-
ternal exposure to endotoxins can also alter the BBB in fetuses
(65). Third, a window of increased susceptibility for hyp-
oxic ischemic insults, stroke, and traumatic brain injury
exists during the perinatal period. It induces exacerbated
brain damage with more dramatic cognitive impairment
when the injury occurs in the developing brain as com-
pared to the sequelae observed in adults following the
same type of injury. In these pathologies, the BBB is
altered. Alterations result from the direct or indirect ef-
fects of free radical formation, excitotoxicity, upregula-
tion of vascular endothelial growth factor, and cytokine
production (reviewed in 63,66). However, whether the
specific perinatal vulnerability of the brain to hypoxic-
ischemic stresses including stroke translates in an exacer-
bated alteration of the BBB remains debated (e.g. 67,68).
Overall, an alteration of the BBB integrity during peri-
natal injuries may increase brain vulnerability to thera-
peutic drugs. This remains to be documented as no effect
of perinatal injuries on cerebral drug delivery has been
reported so far.
Perinatal insults may alter the capacity of blood-brain in-
terfaces to protect the brain in a more subtle way and affect
mainly efflux transporter functions. Pathologic neonatal jaun-
dice, occurring when the plasma bilirubin concentration ex-
ceeds the albumin binding capacity, induces permanent neu-
rological sequelae. Unbound bilirubin readily crosses blood-
brain interfaces and is toxic to neural cells, impairing normal
brain development. Bilirubin is a substrate for ABCC1 located
in the choroid plexuses. Exposure of choroid plexuses to
bilirubin does not impair the tightness of the BCSFB junc-
tions, but specifically leads to a decrease in ABCC1 pro-
tein level in the epithelial cells, thus weakening the barrier
efflux properties (69). Repeated administration of antena-
tal glucocorticoids downregulates ABCB1 expression in
the BBB during the early postnatal period (70), a phe-
nomenon that seems exacerbated by exposure to inflam-
matory mediators (71). Expression levels of Abcb1, Abcg2
and Slc22a8 genes is also decreased in cerebral endothe-
lial cells isolated from the injured brain region one day
after stroke in rat neonates (68). Thus, by altering the
structural and/or biochemical barrier properties of the
BBB and BCSFB, various perinatal or postnatal injuries
may favor drug penetration in the developing brain, and
in most instances enhance the risk of ADRs.
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CONCLUSION
Both the blood-brain and the blood-CSF interfaces are effi-
cient barriers toward the entry of polar drugs into the neonatal
and postnatal brain. Efflux transporter-mediated barrier
mechanisms acting on more lipophilic compounds are likely
to be efficient around birth at the BCSFB, whose barrier
properties mature at an early fetal stage. The degree of pro-
tection may not be so precocious at the BBB, where the ex-
pression of several transporters is downregulated by compar-
ison to the adult levels. Additional characteristics of the devel-
oping brain, independent of the barrier permeability, are also
important factors setting the cerebral concentration of drugs.
Finally, changes in barrier properties induced by perinatal
pathologies can alter the permeability of blood-brain inter-
faces to drugs. Our current knowledge of the different factors
influencing CNS drug bioavailability in the developing brain
is only partial. Further thorough investigations are needed
before the risks of CNS adverse effects can be safely managed
when treating neonates and infants, as well as pregnant wom-
en and breast feeding mothers.
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